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ABBREVIATIONS
ER  : Estrogen Receptor
PR  : Progesterone Receptor
HER 2 NEU  : Human epidermal growth factor receptor 2
EGFR  : Epidermal growth factor receptor
HoxD10        : Homeobox D10
CDH1           :  Cadherin-1
P53               :  Protein 53
DNA  : De oxy ribonucleic acid
IHC  : Immunohistochemistry
PCR  : Polymerase chain reaction
RT PCR  : Reverse Transcriptase Polymerase Chain
  Reaction
IDC NOS  : Invasive ductal carcinoma not otherwise specified
ICMR  : Indian Council of Medical Research
WHO  : World Health Organisation
FISH  : Fluorescent in situ hybridization
cDNA  : Complementary deoxy ribonucleic acid
mRNA  : Messenger ribonucleic acid
ACTB1  : Actin beta 1
CT  : Threshold cycle
??CT  : Delta delta threshold cycle
N  : Number of cases
SD  : Standard deviation
EC  : E Cadherin
HMW CK  : High molecular weight cytokeratin
DCIS  :  Ductal carcinoma in situ
GCDFP    :  Gross cystic disease fluid protein
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1INTRODUCTION
Breast carcinoma is the most common cause of cancer related
mortality in urban Indian women overtaking cervical cancer. The
incidence is 30 – 33 per 1,00,000 women in urban India and it is the
second commonest cause in rural women.1There is a gradual rise in the
incidence of breast carcinoma worldwide. It accounts for about 23% of
all cancers in women.2 Early detection and treatment can certainly reduce
the mortality rates.
Breast cancers exhibit widely varying behaviour with regard to the
likelihood of recurrence, metastasis and response to therapy.Study of
tumour molecular characteristics has enhanced our understanding of both
the risk of breast cancer recurrence and the response to therapy. Hundreds
of putative markers have been identified by immunohistochemistry or
bioassays and thus serve as an important prognostic and predictive factor.
          Some of the genes implicated in breast cancer progression and
evaluated in this study include the p53, E Cadherin and the HoxD10
gene.
One of the most commonly mutated genes in human cancer is
p53.3Alteration  of  this  tumour  suppressor  gene  is  a  critical  step  in  the
development of cancers.4 The gene is present on chromosome 17p, and
produces a nuclear phosphoprotein. The protein functions as a
2transcription factor and regulates entry into S phase of the cell cycle.5,6
The p53 protein also influences the occurrence of apoptosis in tumour
cells.7 Research has shown p53 gene mutation in breast cancers is
associated with worse prognosis.8IHC detects mutant p53 protein in the
cells as a result of conformational changes in the polypeptide which
results in increased stability.9
E Cadherin (EC) is a calcium regulated adhesion molecule present
in most normal epithelial cells and is a classic tumour suppressor gene.10
The EC gene, CDH1 is located on chromosome 16q22.1.2.11It  helps  in
formation of glands, epithelial polarization and stratification.12Loss of EC
results in dedifferentiation and invasion in carcinomas.13 While majority
of the infiltrating lobular carcinomas show a complete loss of EC
expression, ductal carcinomas show heterogeneous loss of EC expression,
due to epigenetic transcriptional downregulation.14 Studies show CDH1
under expression to be associated with histological type, higher tumour
grade, stage and nodal status.15
The Hox gene network is essential for spatio temporal cell
localisation  and for cell to cell signal decoding so as to attain phenotype
cell identity.16 The thoracic Hox genes are involved in breast
organogenesis,17 whereas the cervical and lumbo-sacral Hox genes are
involved in progression of breast cancer.18 The genes indicated in breast
3cancer progression include HoxD10, B13, A11 in lumbo sacral part and
HoxB2, D3, D4 in cervical part.19
In this study of 60 cases of invasive ductal carcinoma NOS, an
attempt is made to evaluate the p53 status by IHC, the HoxD10 and E
Cadherin status by PCR and to correlate them with histological grade and
other prognostic factors.
4AIMS AND OBJECTIVES
1. To identify the relative frequency and distribution of breast
carcinoma in the population.
2. To study the histomorphological features of breast carcinoma
including grade, lymph node status, lymphovascular invasion,
lymphocytic response and necrosis.
3. To study the immunohistochemical expression of p53 in invasive
carcinoma breast.
4. To study the E Cadherin and HoxD10 gene expression by PCR in
invasive carcinoma breast.
5. To assess the correlation between p53 status, E Cadherin and
HoxD10 gene expression and with other known prognostic factors
like histological grade, tumour size, axillary node status, tumour
necrosis, lymphocytic response, lymphatic and vascular invasion
by tumour.
5REVIEW OF LITERATURE
Invasive breast carcinomas are a group of malignant epithelial
tumours which show invasion of the adjacent tissues, with an increased
tendency for distant metastasis.20Breast carcinoma is one of the cancers
commonly described in ancient documents due to its visibility.
The Edwin Smith Papyrus gives the oldest description of breast cancer,
discovered in Egypt and dating back to1500 BC.21 First documented case
of breast cancer was described by Imhotep in 2650 BC.
Leonides (30 AD) compared cancers to crabs, due to the tenacious
adherence to the surrounding tissues. In 1874, Paget described the
changes in the nipple that preceded breast cancer and it continues to bear
his name.22
Radical mastectomy was first performed by William Stewart
Halsted in 1882.23 X-rays were discovered by Wilhelm Conrad Röntgen
in1895 and it forms the basis for mammogram and radiotherapy.24
In 1925, Greenhough was the first to evaluate grading system for
breast cancer.25  In 1928, Scarff et al proposed tubule formation, nuclear
pleomorphism and hyperchromasia as criteria to grade breast cancers. In
1957,Bloom and Richardson proposed the numeric scoring system based
on tubule formation, nuclear pleomorphism and mitosis for grading
6adapted by WHO.26 In 1983, Bloodgood et al recognized ductal
carcinoma in situ where neoplastic cells are limited within the terminal
duct lobular unit.27 Early 1990, Nottingham modification of Bloom
Richardson grading system was adapted by WHO.28
EPIDEMIOLOGY
According to the 2001-03 ICMR report, breast cancer constitutes
about 25% of the total cancers among Indian women.29 Breast cancer is
the most common cancer in metropolitan cities and the second most
common in rural Indian women after cervical cancer.
In India, the crude incidence rate of breast carcinoma is 85/100,000
women/ year.30 The death per incident ratio is highest in India, with 50%,
compared to 30% in China and 18% in the US.31
The annual age-adjusted rate is 30 to 33 per 100,000 in urban
women and 8.6 per 100,000 in rural women.32
India is rapidly stepping towards industrialization resulting in
lifestyle changes. This probably contributes to the increase in breast
cancer incidence in our country.
The presenting symptoms include breast lump, nipple discharge,
retraction or eczema. Screening for breast abnormalities are done by the
7triple assessment which includes clinical examination, imaging and tissue
sampling.
RISK FACTORS
The risk factors strongly associated with breast cancers include
early menarche, late menopause, nulliparity, older age at first child birth,
sedentary life style with high caloric diet, obesity, use of exogenous
oestrogens and positive family history in a first degree relative.33
ETIOLOGY
The main etiological factors of breast carcinoma include hormone
excess and genetics.
Oestrogen and breast cancer
The main function of oestrogen is stimulation of cell growth and
proliferation by acting via oestrogen receptor (ER) as a transcriptional
activator.34 However, this process is slow. Recently, a non genomic
pathway has been demonstrated which does not involve ER, but acts
through a G-protein coupled receptor, GPR30.  This results in activation
of metalloproteinases and cleavage of heparan-bound EGF (epidermal
growth factor). The released EGF then acts on its receptor, EGFR and
stimulates cell proliferation.35 The existence of this pathway indicates
8that drugs acting only through ER may not be enough to inhibit tumour
growth.
Fig.1: Proposed precursor-carcinoma sequences in breast cancer
Genes involved in Breast Cancer
About 5% to 10% of breast cancers are thought to be hereditary.
The genes which increase the risk of developing breast cancer include
the BRCA1, BRCA2, PTEN,CDH1, STK11 and the TP53 gene.
BRCA1 and BRCA2 are the major genes involved in hereditary
breast cancer. The BRCA1 gene is present on chromosome 17q and its
product is responsible for DNA repair. Women with these mutations have
an increased risk of developing breast cancer, ovarian cancer and
pancreatic cancer.36,37 BRCA2 gene mutations are associated with high
risk of developing carcinoma of the male breast, cancers of the pancreas,
prostate and cutaneous melanoma.38,39
9Invasive ductal carcinoma is a group of breast carcinoma in which
the stromal invasion of malignant cells is evident beyond the epithelial
component. Current histomorphological subtyping of breast carcinoma is
based on World Health Organisation classification (Annexure II).
INVASIVE DUCTAL CARCINOMA NOT OTHERWISE
SPECIFIED (IDC NOS)
         This is the most common type of breast cancer, accounting for 75-
80% of the breast cancers.40 These tumours elicit a marked fibroblastic
stromal reaction and produce a firm palpable mass. It may produce
dimpling of the skin due to traction on the suspensory ligaments. Grossly,
the tumour is ill defined, firm, with a yellow grey cut surface, with
radiating trabeculae into the surrounding parenchyma, resulting in a
stellate appearance.
Histologically, the tumour cells are arranged in a variety of
patterns such as acinar configurations, cords and broad sheets of cells,
with  surrounding  dense  stroma.  The  tumours  show  a  wide  range  of
differentiation with poorly differentiated tumours showing solid sheets of
pleomorphic cells. These tumours are graded using Nottingham
modification of Scarff Bloom Richardson system (Annexure III).
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INVASIVE LOBULAR CARCINOMA
Lobular carcinoma is the second commonest type of breast cancer
accounting for 10% of the cases. The tumour is more often bilateral and
multicentric.
The  amount  of  stromal  reaction  varies  from  scanty  to  dense
desmoplasia and therefore it may present as a discrete mass or diffuse
indurated area.
The tumour cells are small, uniform and bland looking, often
arranged in Indian file pattern or may form concentric arrays around
ducts resulting in targetoid pattern. 10% of cases show mixed features of
invasive ductal and lobular carcinomas.
It is characterised by the presence of HMW keratin, lack of
accumulation of p53, and most importantly  decrease or absence of E-
cadherin.41,42,43 To these, p120 catenin has been recently added, supported
by the claim that lobular carcinoma shows a characteristic cytoplasmic
staining pattern with this marker.44
MEDULLARY CARCINOMA
It is common in patients under 50 years of age, particularly in
BRCA1 mutations carriers.45 Grossly, the tumour is well circumscribed.
Its cut surface is homogeneous, solid and grey with occasional foci of
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necrosis. Microscopy shows solid sheets of large pleomorphic cells with
prominent nucleoli, forming a syncytium. The tumour has scant fibrous
stroma and frequent mitotic figures. Numerous lymphocytes surround the
sheets of tumour cells with most of them being cytotoxic
T lymphocytes.46 They typically express CK7, often express vimentin,
S-100 and P53, but not CK20.47 They are almost invariably negative for
hormone receptors as well as c-erbB-2 (‘triple negative’ phenotype).
MUCINOUS CARCINOMA
It commonly occurs in postmenopausal women. Grossly, it is well
circumscribed, with a glistening jelly like mass held together by delicate
septa. Microscopically, the tumour cells form small clusters and appear to
float in a sea of mucin. These clusters may be solid, exhibit acinar
formations or form micropapillary structures.48 Histochemically, the
mucins secreted by this tumour are distinct O-acylated forms of
sialomucins.49 Immunohistochemically, there is strong MUC2
cytoplasmic immunoreactivity and decreased MUC1 immunoreactivity
compared with ductal carcinoma NOS.50 Hormone receptors are always
positive, while c-erbB-2 is almost always negative.
TUBULAR CARCINOMA
It commonly occurs in patients around 50 years of age. Grossly, it
is characteristically small, measuring about 1cm with poorly
12
circumscribed margins and hard consistency. Microscopically, it is
characterised by the haphazard arrangement of irregular and angulated
glands in a desmoplastic stroma with the lining cells being small and
regular. Low-grade DCIS and flat epithelial atypia are thought to be
precursor lesions of tubular carcinoma.51,52
CRIBRIFORM CARCINOMA
These tumours accounts for 0.8 to 3.5% of breast carcinomas.
Histologically,  more  than   90%  of   tumour   shows   cells  arranged  in
islands in which well-defined spaces are formed by arches of cells
resulting in a sieve like or cribriform pattern.
INVASIVE PAPILLARY CARCINOMA
These tumours accounts for less than 1 to 2 % of breast carcinoma.
Fischer et al first reported that invasive papillary carcinoma is grossly
circumscribed. Microscopically, the cells are arranged as delicate or blunt
papillae with amphophilic cytoplasm.
INVASIVE MICROPAPILLARY CARCINOMA
The tumour is composed of small clusters of cells lying within
clear stromal spaces resembling dilated vascular channels. They account
for less than 2% of the breast cancers.
13
APOCRINE CARCINOMA
It accounts for 1- 4% of the breast cancers.>90% of the tumour is
composed of apocrine cells.53 There are 2 types of apocrine cells – Type
A cells have abundant eosinophilic granular cytoplasm and Type B cells
have  clear,  foamy cytoplasm.  It  is  typically  positive  for  GCDFP-15  and
negative for bcl2 protein, ER and PR.
METAPLASTIC CARCINOMA
It account for less than 1% of the breast cancers. The neoplasm is
heterogeneous,showing intimate admixture of adenocarcinoma with areas
of spindle, squamous or mesenchymal differentiation ranging from
chondroid and osseous differentiation to frank sarcoma.Grossly, they
present as well delineated, firm, pearly white glistening mass.
NEUROENDOCRINE CARCINOMA
They constitute about 5% of all breast carcinomas. It comprises
carcinoid tumours, large cell neuroendocrine carcinomas and small cell
carcinomas. Microscopically, the neoplastic cells are small, arranged in
solid nests separated by fibrous stroma. Ribbons and rosette like
formations may be seen. Mitoses are generally rare. They express
neuroendocrine markers in more than 50% of the tumour cells, and this
feature helps to distinguish them from breast carcinoma with focal
endocrine differantiation.54
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PROGNOSTIC FACTORS
Patient's age: Women younger than 50 years of age have the best
prognosis. Relative survival declines after 50 years.
Size: The tumour size shows a good correlation with the nodal status and
survival rate.55,56
Cytoarchitectural type: There is no significant prognostic difference
between ordinary invasive ductal and invasive lobular carcinoma.57
Morphologic variants of invasive ductal carcinoma with a more
favourable prognosis are medullary carcinoma, mucinous carcinoma,
tubular carcinoma, cribriform carcinoma,  papillary carcinoma, adenoid
cystic carcinoma and secretory  carcinoma.58 Squamous cell carcinoma,
metaplastic carcinoma, carcinomas with neuroendocrine features, and
signet ring cell carcinoma behave in an aggressive way.59
Microscopic grade: Tumours are graded based on Nottingham
modification of the Scarff Bloom–Richardson system (Annexure III).
Ellis et al reported this grading system to have excellent correlation with
patients’ survival and rate of metastasis.28
Axillary lymph node metastases: This is an important prognostic factor.
There is a marked difference in survival between patients with positive
and negative nodes and the survival rate also varies depending on the
level of axillary node involved, their absolute number,60 the  amount  of
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tumour cells in the node,61 the presence or absence of extranodal spread
and the presence or absence of tumour cells in the efferent vessels.
Other factors reported to have poor prognosis include tumour
necrosis, lymphocytic infiltration and skin infiltration. After the advent of
immunohistochemistry and polymerase chain reaction, more molecular
biomarkers play significant predictive as well as prognostic role in breast
cancer management.
IMMUNOHISTOCHEMISTRY (IHC)
IHC is a molecular technique which was first described by
Dr.Albert Coons in 1941. The original method consisted of an antibody
developed in rabbits and then tagged with a fluorescent probe. It was
mixed with tissue sections and examined using a fluorescent microscope
after a period of incubation. Since then, numerous advancements have
been made.62 The most commonly used techniques are the peroxidase-
antiperoxidase immune complex method developed by Sternberger in
1970 and the biotin-avidin immunoenzymatic technique developed by
Heitzman and Richards in 1974.63,64
USES OF IMMUNOHISTOCHEMISTRY IN BREAST
PATHOLOGY65,66
1. The use of myoepithelial markers to assess stromal invasion.
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2. E Cadherin to differentiate between ductal and lobular carcinoma.
3. High molecular weight cytokeratins to distinguish between usual
ductal hyperplasia and ductal carcinoma in situ.
4. To find the site of origin in metastatic cancers.
5. Cytokeratin stain to detect sentinel lymph nodes metastasis.
6. Assessment of Estrogen and Progesterone receptor status &
HER2neu overexpression using specific antibodies to receptor
proteins.
7. Evaluation of spindle cell lesions to distinguish metaplastic
carcinoma from mesenchymal lesions.
ANTIGEN RETRIEVAL
Shi et al in 1991developed the antigen retrieval technique, in which
he used a heating method at high temperatures to bring out the
antigenicity of the tissue which had been masked by formalin fixation.
Antigen retrieval can be done by heat induced epitope retrieval or
proteolytic induced epitope retrieval.
HEAT INDUCED EPITOPE RETRIEVAL
The technique involves application of heat for varying period of
time to the tissue sections in the retrieval solution. This results in
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breakdown of protein cross-links formed by formalin fixation and
recovers the tissue antigenicity.67
Some of the commonly used heating devices are the microwave
oven, pressure cooker, steamer, autoclave and water bath. Heating is
usually done for about 20 minutes followed by 20 minutes of cooling.
The retrieval solution commonly used is the Citrate buffer with pH 6.0.
Other retrieval solutions include the TRIS-EDTA with pH9.0 and EDTA
with pH8.0.
PROTEOLYTIC INDUCED EPITOPE RETRIEVAL 68
Proteases like proteinase K, trypsin, chymotrypsin and pepsin are
used to restore the tissue antigenicity. However, this technique can
destroy some epitopes and alter the tissue morphology. Therefore the
optimal concentration of the enzyme and incubation time needs to be
validated.
TARGET ANTIGEN DETECTION METHODS
After addition of specific antibodies to the antigens, next step is to
visualize the antigen antibody reaction complex. The methods employed
are the direct and the indirect methods.
The direct method is a one step staining procedure in which a
labelled antibody directly reacts with the antigen in the tissue sections.
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Most commonly used labels are fluorochrome, horse radish peroxidase
and alkaline phosphatase. Although this method is simple, rapid, and uses
only one antibody, the sensitivity is lower. This is because signal
amplification is less, and therefore it is not as commonly used when
compared to the indirect methods.
In the indirect method, first layer is formed by an unlabelled
primary antibody which binds to the target antigen. Then, a second layer
is formed by using a labelled secondary antibody that reacts with the
primary antibody. This technique is more sensitive than the direct method
because  of  better  signal  amplification.  This  is  due  to  the  binding  of
several secondary antibodies with conjugated fluorochrome to each
primary antibody. Another advantage with this method is that it uses only
a small number of secondary antibodies.69
TP53
It was first discovered by Lane et al in1979 and it has been found
to be one of the most commonly mutated gene in human cancers
(Hollstein, 1991). The TP53 gene is present on chromosome 17p.70 It
produces a 393 amino acid phosphoprotein, which is normally present at
a low level in the cells.71
The p53 gene functions as a tumour suppressor and inhibits cell
proliferation and plays a role in inducing cellular differentiation and
19
apoptosis. Wild-type p53 blocks the cell cycle near the GI/S phase.72 IHC
detects nuclear accumulation of the protein, occurring due to
conformational changes, resulting in a prolonged half-life.73,74 The p53
mutation rate in breast tumours is 20-40%.75 p53 over expression in
tumours are associated with higher histological grade, increased mitotic
activity, aggressive behaviour and hence a worse prognosis.76
POLYMERASE CHAIN REACTION (PCR)
PCR is a technique in molecular biology which involves repeated
cycles of DNA denaturation, annealing with primer, followed by
extension with DNA polymerase resulting in the amplification of a piece
of DNA, generating millions of copies of a particular DNA sequence.
The invention of PCR in 1983 is credited to Kary Mullis.77 The
DNA polymerases initially used were unable to withstand high
temperatures.78 So the earlier methods for DNA replication were very
inefficient, requiring large amounts of DNA polymerase and constant
handling throughout the entire process.
In 1988, Saiki et al proposed the use of Taq polymerase, a DNA
polymerase obtained from the thermophilic bacterium, Thermus
Aquaticus. This resulted in dramatic improvements of the PCR method. It
is stable at high temperatures and remains active even after DNA
denaturation. Thus, it obviates the need to add a new DNA polymerase
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after each cycle and hence an automated thermocycler-based process
could be used for DNA amplification.79,80 This technique showed
increased specificity but with 40% of amplified DNA fragments showing
altered base due to absence of proof reading activity. In 1996, Cline J et
al developed an alternative heat stable DNA polymerase derived from
Pyrococcus furiosus and Thermococcus Litoralis with 3` to 5`
exonuclease activity. This technique showed only 3.5% of DNA with
altered base. In 1992, Higuchi et al first documented real time PCR that
enabled the quantification of gene expression and DNA copy
measurements.81
PCR requires the following components: template, primer,
deoxyribonucleotides, DNA polymerase, buffer solution, magnesium and
potassium ions.82 Also, part of the target DNA sequence needs to be
known so as to design an appropriate primer. The first step is
denaturation, where the target DNA is heated above  90°C (194°F). This
procedure  results  in  separation  of  the  two strands  of  DNA.  Each  strand
can now function as a template. The second step is annealing of the
primers with their respective complementary sequence on each template
and is carried out at 50°C (122° F). In the third step, primer extension is
done using DNA polymerase and provided nucleotides. Hence, the
numbers of DNA molecules double at the end of each cycle.83
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Reverse transcription-PCR (RT-PCR) is a sensitive method for
detecting   mRNA  expression  levels.  RT-PCR  consists  of  two  steps:  the
RT reaction and PCR amplification. First, RNA is reverse transcribed
into cDNA using a reverse transcriptase. The resulting cDNA can then be
used as templates and PCR amplification is done using specific primers.
There is  also a one step RT-PCR in which all  the reagents are added in
one tube prior to starting the process. Though it is simple, convenient,
with minimal risk of contamination, the cDNA produced cannot be
repeatedly used as in two step RT-PCR.84
In 1988, Haqqi et al. developed nested PCR. Its purpose is to
decrease the contamination in products due to the amplification of
unwanted primer binding sites. The procedure uses two sets of primers in
two successive runs of PCR.  The second set amplifies a target within the
product of the first run. The basic idea is that if the wrong locus was
amplified, there is a very low probability that it would also be amplified a
second time by the second set of primers.
In 1988, Chamberlain et al. described multiplex PCR where
different target sequence can be amplified simultaneously in a single
reaction using different primers. Competitive PCR is a process of co
amplification in same reaction tube of 2 different templates of equal
length and with same primer binding sequences.
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Real time PCR involves amplification and simultaneous
quantification of a targeted DNA sequence. The quantity could either be
an absolute number of copies or a relative amount when normalized to
the DNA input.
A key feature of  this  procedure is  that  the amplified DNA can be
detected as the reaction proceeds in real time. Whereas, in standard PCR,
the reaction product is detected at the end. Products in real-time PCR are
detected by: (1) non-specific fluorescent dyes which integrate with any
double stranded DNA and (2) sequence specific DNA probes consisting
of fluorescent labelled oligonucleotides that permits detection only after
binding of the probe with its complementary DNA sequence.85
Frequently, real-time PCR and reverse transcription are combined
in order to quantify mRNA and non-coding RNA in tissues.
Advantages of PCR include high speed, ease of use, high
sensitivity and its ability to amplify the desired target DNA sequence.
A limitation of PCR is that only 0.1- 5 kb size DNA sequences can
be amplified. The amplification product levels off due to finite enzyme.
ROLE OF HOX D10 GENE IN BREAST CANCER
HOXD10 is a sequence-specific transcription factor which
regulates the developmental system and provides cells with specific
23
positional identities on the anterior-posterior axis. It is a member of the
Abd-B homeobox family and is present on chromosome 2. It encodes a
nuclear protein which functions as a sequence specific transcription
factor which is essential for limb development and differentiation.
Apart from its role in embryogenesis, Hox genes are also active in
adult cells where they regulate the genes which are involved in cellular
proliferation and also cell-cell and cell-extracellular matrix signalling. It
is widely established that several Hox genes show an altered pattern of
gene expression in certain malignancies like leukemia and solid
neoplasms such as breast, endometrium, brain, colon, prostate, lung, and
kidney. Research has shown that loss of various Hox genes is often
associated with the development of tumour.
Breast cancer is characterised by a progressive loss of epithelial
cell polarity, growth control, macrophage infiltration and increased
angiogenesis. While HoxD10 gene shows high expression in normal
breast epithelial and endothelial cells, invasive breast carcinomas show
progressive loss of HoxD10 in both breast epithelial and endothelial cells.
Studies have shown restoration of HoxD10 gene in metastatic breast
cancer cells, results in growth arrest and cell polarisation. Also,
restoration of HoxD10 in angiogenic endothelium blocks angiogenesis.86
HoxD10 also suppresses the chemokine expression in tumours which
evokes an inflammatory reaction. Thus, HoxD10 is a potent tumour
24
suppressor gene which directly impacts the epithelial cells and inhibits
angiogenesis and inflammation, thus stabilizing the tumour
microenvironment.87
Fig.2: Regulation of tumor metastasis by HoxD10
Breast cancer metastasis suppressor-1 (BRMS1) regulates Twist
expression. Elevated expression of the transcription factor Twist in breast
cancer cells induces the transcription of miR-10b which suppresses the
synthesis of the HOXD10 protein, a negative regulator of breast cancer
progression, permitting expression of pro-metastatic gene products, RhoC
and p21-activated kinase1(Pak1). This in turn favours cancer cell migration,
invasion, and metastasis.
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ROLE OF E CADHERIN GENE IN BREAST CANCER :
E Cadherin is a tumour suppressor gene present on chromosome
16. Most epithelial tissues show cell surface expression of E Cadherin
(Takeichi, 1990).  It is considered to be a key molecule in the formation
of intercellular junctions and for establishing the cell polarization
(Gumbiner et al,1988). The cytoplasmic tail of E-cadherin is linked to the
actin cytoskeleton via catenins (Cowin, 1994) and the extracellular
domain is involved in mediating cell–cell adhesion (Shapiro et al, 1995).
E Cadherin under expression leads to invasion in breast cancer
(Siitonen et al, 1996), cancer progression and metastasis. E Cadherin
activation can cause growth retardation of cancer cells (Navarro et al,
1991; St Croix et al, 1998)
Partial  or  complete  loss  of  E  Cadherin  expression  leads  to
dedifferentiation, invasion, higher tumour grade, metastasis and worse
prognosis in breast cancer.88
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MATERIALS AND METHODS
This study is a prospective and retrospective descriptive study of
invasive breast cancers conducted in the Institute of Pathology, Madras
Medical College and Government hospital, Chennai during the period
between Jan 2010 to Feb 2012.
Source of data
The invasive ductal carcinoma cases reported in mastectomy
specimen received in the Institute of Pathology,  Madras Medical College
between Jan 2010 to Feb 2012 from the Department of Surgery,
Oncology, Plastic surgery and Geriatrics, Government General Hospital.
A total of 274 mastectomy specimens (simple, modified radical or radical
mastectomy) were received during this period.
Inclusion criteria
All the invasive ductal carcinoma cases reported in mastectomy
specimens irrespective of the age and sex were included for the study.
Exclusion criteria
? Non neoplastic lesions and benign tumors of breast.
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? Ductal carcinoma breast reported in incision/excision biopsy and
completion mastectomy specimens.
? Cases with inadequate material from the tumor for doing both
immunohistochemistry and polymerase chain reaction were not
included in the study.
METHOD OF DATA COLLECTION
Detailed history of the cases regarding age, sex, menstrual history,
side of the breast, type of procedure, history of neo adjuvant therapy,
details of gross characteristics such as tumour size, nodal status details
were obtained for all the 274 mastectomy cases reported during the
period from surgical pathology records. Freshly cut, hematoxylin & eosin
stained 4 µ thick sections of the paraffin tissue blocks of mastectomy
specimens were reviewed and graded using the Nottingham modification
of the Scarff  Bloom Richardson Grading system (Annexure III) and they
were further evaluated for the presence of necrosis, lymphocytic response
and lymphovascular invasion by tumour. 20 cases of each grade from
Invasive ductal carcinoma NOS subtype were randomly selected from the
total cases and their representative formalin fixed paraffin embedded
tissue samples were subjected to p53 immunohistochemical analysis and
to HoxD10 & E Cadherin gene analysis (using fresh tissue) by PCR. Due
to economic constraints, CDH1 gene analysis was done only for 25 cases.
The results were recorded with photographs.
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IMMUNOHISTOCHEMICAL EVALUATION
Immuohistochemical analysis of p53 was done in paraffin
embedded tissue samples using Supersentive polymer HRP system based
on non biotin polymeric technology.
Antigen Vendor Species Dilution Positive control
P53 BIOGENEX mouse Ready to
use
Breast
4 µ thick sections from selected formalin fixed paraffin embedded
tissue samples were transferred onto gelatin coated slides. Heat induced
antigen retrieval was done. The p53 antigen is bound with mouse
monoclonal antibody (Biogenex) and then detected by the addition of
secondary antibody conjugated with horse radish peroxidase-polymer and
Diaminobenzidine substrate. The step by step procedure of
Immunohistochemistry is given in Annexure IV.
INTERPRETATION & SCORING SYSTEM
p53 positivity can be seen in the nucleus of tumour cells. An
estimation of  >10% nuclei distinctly stained with anti p53 antibody was
taken as positive.89
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REAL TIME POLYMERASE CHAIN REACTION FOR HOXD10
ISOLATION OF TOTAL RNA
Sections of 10µ thickness were collected from all the formalin
fixed paraffin embedded tissue samples.  Total RNA from the samples
were purified with RNeasy kit (Qiagen) and stored in collection tubes at
-20ºC to -70ºC. (Step by step procedure given in Annexure V). The
concentration of total RNA isolated from each sample was determined by
measuring the absorbance at 260nm in a spectrophotometer. The volume
of each sample containing 5ng of total RNA was calculated.
REAL TIME PCR AMPLIFICATION
The real time one step polymerase chain reaction is carried out
with  Rotor  Gene  Q system using  Rotor  gene  SYBR green  RT PCR kit.
Normal breast tissues obtained from autopsy material were used as
controls to study the relative gene expression in breast cancer. ? actin 1
(ACTB1) is used as house keeping gene in this study. Samples were run
in duplicates for both HoxD10 and ACTB1 gene.
To check the efficiency of  the RT PCR a standard curve with log
concentration obtained by dilution of control sample was generated for
both HoxD10 and ACTB1 gene simultaneously. The concentration
dilutions were 100ng, 10ng and 1 ng respectively.
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HoxD10 gene and ? actin gene were amplified using the extracted
RNA as templates and the following forward and reverse primers.
HoxD10 forward (5?CCCTTACACCAAGCACCAAACG) primers,
HoxD10 reverse (5?CTCGGATCCTGGCCTCACATC) primers,
? actin forward (5'CCCCTGGCCAAGGTCATCCATGACAACTTT-3')
primers&
? actin reverse (5'GGCCATGAGGTCCACCACCCTGTTGCTGTA-3')
primers.
The PCR was carried out as follows,
? Thaw 2x Rotor gene SYBR green RT PCR master mix, RNA
template, primer and RNAse free water to prevent premature
complementary DNA synthesis.
? The reaction mix was prepared in PCR tubes as follows
? 2xRotor gene SYBR green RT PCR master mix - 12.5 ml
? Rotor gene RT mix - 0.25 ml
? Primer for HoxD10/? actin - 2.5 ml
? Template RNA of each sample with concentration of 5 ng
? The total reaction volume was made into 25 µl with RNAse
free water.
? The PCR tubes were placed in Rotor Gene cycler and the cycling
conditions were programmed as follows
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STEP TEMPERATURE TIME
Reverse transcription 55ºC 10 minutes
PCR Initial activation step 95ºC 5 minutes
One step PCR cycling x 40 cycles
Denaturation 95ºC 5 seconds
Combined
annealing/extension 60ºC 10 Seconds
? Melting curve analysis was performed at the end of reactions with
temperature range of 55ºC to 95ºC to check the specificity of the
reaction.
RELATIVE GENE EXPRESSION ANALYSIS
The HoxD10 RNA levels were calculated in the breast cancer
samples and normal breast tissue in a relative quantification approach by
using a reference gene ACTB1. Relative expression was calculated by
deriving the delta delta CT values for HoxD10 with reference to ACTB1
gene expression. These values were generated automatically by Rotor
Gene Q 2 Plex series software version 1.74. Relative concentration of
HoxD10  RNA  in  tumour  samples  to  that  of  control  samples  was
calculated as a linear value from the equation 2-??? CT. These values were
subjected to statistical analysis.
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POLYMERASE CHAIN REACTION FOR E CADHERIN
SAMPLE COLLECTION
 A small piece of the tumour tissue and the adjacent normal tissue
were collected in sterilized vials containing saline.
DNA EXTRACTION
? DNA was extracted by phenol- chloroform method.
?  The tissue was homogenized with lysis buffer.
? The digested mixture was then incubated with proteinase K
enzyme. The mixture was then centrifuged.
? This was followed by phenol treatment. The mixture was again
centrifuged.
?  The aqueous layer was collected and treated with 10M Nacl. The
mixture was again centrifuged and the supernatant was treated with
ethanol and the DNA precipitated by centrifugation.
AMPLIFICATION OF E-CADHERINS
Primers used for PCR amplification of E-cadherin exons were as
per the sequences described by G.Berx et al,1995.The amplification for
each amplicon was optimized for annealing temperature and for MgCl2
concentration.The amplified PCR product was then subjected to agarose
gel electrophoresis.
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MUTATIONAL SCREENING
The amplified E-cadherin gene was then sequenced and compared
with the sequence of DNA isolated from normal tissue for the presence of
mutation.
STATISTICAL ANALYSIS
The statistical analysis was done using the statistical package for
social science software version 11.5. Correlation between P53& E
Cadherin expression and clinicopathological prognostic factors such as
tumour size, nodal status, necrosis and lymphovascular invasion was
analysed using Pearson chi square test.
The efficiency of the real time PCR experiment derived from
standard curve was within a range of 0.82 and 0.86 for HoxD10 and
ACTB1 reference genes respectively elucidating the validity of
experiment. Standard curve from first set was used for the other set runs
subsequently. Melt curve analysis showed minimized range of primer
dimers with peaks at 75ºC.
The expression of HoxD10 gene was non parametric, so the
correlation with other prognostic factors was done using Mann Whitney
U test, student t test and Kruskal-Wallis Test.
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OBSERVATION AND RESULTS
In the study period of 26 months from Jan 2010 to Feb 2012, a
total of 21,566 specimens were received in the Institute of Pathology,
Madras Medical College for histological examination.
Total numbers of breast specimens received were 1,301 cases, of
these breast tumours accounted for 912 cases with a percentage of 4.23%
of all cases (both incisional biopsies and mastectomy specimens).
The relative frequency of breast cancers among the specimen
received was 2.04%.
The total number of non neoplastic, benign and malignant cases
were 389, 472 and 440 respectively. Thus the distribution of non
neoplastic breast lesions were 29.90%, benign tumours were 36.28% and
of malignant tumours were 33.82%.
Out of a total of 440 breast cancer cases, only 274 cases constituted
mastectomy specimens.
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The age wise distribution of these 274 cases is given below (Table 1 and
Chart 1)
Table 1: Age wise distribution of Breast Cancers
AGE GROUP NUMBER OFCANCERS PERCENTAGE
21- 30 years 6 2.20 %
31-40 years 53 19.3 %
41- 50 years 96 35 %
51- 60 years 75 27.4 %
61- 70 years 32 11.7 %
>70 years 12 4.4 %
Total cases 274 100 %
Breast cancers had the highest incidence in the 41-50 year age group.
Chart 1
The youngest age of presentation of breast cancer is at 25 years in
this study.
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The distribution of histological subtypes of breast carcinoma is
shown in Table 2 & Chart 2.
Table 2: Distributions of Histological Subtypes of Breast Cancers
S.
NO HISTOLOGICAL SUBTYPES
NO.OF
CASES PERCENTAGE
1 Invasive ductal carcinoma NOS 246 89.78 %
2 Invasive lobular carcinoma 2 0.73 %
3 Mucinous carcinoma 5 1.83 %
4 Papillary carcinoma 4 1.46 %
5 Micropapillary carcinoma 2 0.73 %
6 Medullary carcinoma 2 0.73 %
7 Cribriform carcinoma 1 0.37 %
8 Metaplastic carcinoma 4 1.46 %
9 Mixed carcinoma 1 0.37 %
10 Neuroendocrine carcinoma 1 0.37 %
11 Apocrine carcinoma 4 1.46 %
12 Malignant phyllodes 2 0.73 %
 Total number of cases 274 100 %
Chart 2
DISTRIBUTION OF HISTOLOGICAL TYPES IN
BREAST CANCER Invasive ductal carcinoma
NOS
Invasive lobular carcinoma
Mucinous carcinoma
Papillary carcinoma
Micropapillary carcinoma
Medullary carcinoma
Cribriform carcinoma
Metaplastic carcinoma
Mixed carcinoma
Neuroendocrine carcinoma
Apocrine carcinoma
Malignant phyllodes
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Among the 274 cases, 272 (99.3%) cases were reported in females
and 2(0.7%) cases were reported in male breast. (Table 3 & Chart 3)
Table 3: Sex Distribution in Invasive Ductal Carcinoma
SEX TOTAL NO. OF CASES PERCENTAGE
Male 2 0.7 %
Female 272 99.3 %
Total 274 100 %
132 cases of Invasive ductal carcinoma were reported in left breast,
141 cases were reported in right breast and 1 case had cancer in both the
breasts. (Table 4 and Chart 4)
Table 4: Distribution of side of involvement in Breast
SIDE NO. OF CASES PERCENTAGE
Left 132 48.1 %
Right 141 51.5 %
Both breasts 1 0.4 %
Total 274 100 %
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20 cases (7.3%) had tumour less than 2 cm in size, 189 cases
(69%) were of 2 to 5 cm in size and 65 cases (23.7%) were more than 5
cm in size. (Table 5 & Chart 5).
Table 5: Distribution of size in Invasive Ductal Carcinoma
SIZE OF TUMOUR NO. OF CASES PERCENTAGE
<2cm(T1) 20 7.3 %
2-5cm(T2) 189 69 %
>5cm(T3) 65 23.7 %
There were 245 Invasive ductal carcinoma NOS type breast
cancers in the study sample which were graded according to modified
Scarff  Bloom Richardson grading system out of which 77 cases(31.43%)
were in grade I, 128 cases (52.24%) were in grade II and 40 cases
(16.33%) were in grade III. (Table 6 & Chart 6)
Table 6: Distribution of Histological Grade in Invasive Ductal
Carcinoma NOS Type
GRADE NO. OF CASES PERCENTAGE
Grade 1 77 31.43 %
Grade 2 128 52.24 %
Grade 3 40 16.33 %
TOTAL 245 100 %
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76 cases (27.7%) had up to 3 nodes with metastatic ductal
carcinomatous deposit, 56 cases (20.4%) had 4 to 10 involved nodes, 12
cases (4.4%) had more than 10 involved nodes, while 130 cases (47.4%)
had no lymph node involvement (Table 7 & Chart 7).
Table 7: Distribution of Lymph Node Metastasis in Breast Cancers
LYMPH NODE STATUS NO OF CASES PERCENTAGE
Negative 130 47.4 %
1-3 positive nodes 76 27.7 %
4-10 positive nodes 56 20.4 %
>10 positive nodes 12 4.4 %
Total 274 100 %
182 cases (66.4%) had lymphatic invasion as against 92 cases
(33.6%) without lymphatic invasion (Table 8 & Chart 8).
Table 8: Distribution of lymphatic invasion in Invasive Ductal
Carcinoma Breast
LYMPHATIC
INVASION NO OF CASES PERCENTAGE
Present 182 66.4 %
Absent 92 33.6 %
Total 274 100 %
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102 cases (37.2%) showed vascular invasion while 172 cases
(78%) cases had no vascular invasion. (Table 9& Chart 8)
Table 9: Distribution of vascular invasion in Invasive Ductal
Carcinoma Breast
VASCULAR
INVASION NO OF CASES PERCENTAGE
Present 102 37.2 %
Absent 172 62.8 %
Total 274 100 %
19  %  of  the  cases  had  skin  infiltration  (Table  10),  58.4%  of  the
cases had lymphocytic infiltration (Table 11)& 27.4% of the cases had
necrosis(Table 12)as shown in Chart 9.
Table 10: Distribution of skin infiltration in Invasive Ductal
Carcinoma Breast
SKIN
INFILTRATION NO OF CASES PERCENTAGE
Present 52 19 %
Absent 222 81 %
Total 274 100 %
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Table 11: Distribution of lymphocytic infiltration in Invasive Ductal
Carcinoma Breast
LYMPHOCYTIC
INFILTRATION NO OF CASES PERCENTAGE
Present 160 58.4 %
Absent 114 41.6 %
Total 274 100 %
Table 12: Distribution of necrosis in Breast Cancer
NECROSIS NO OF CASES PERCENTAGE
Present 75 27.4 %
Absent 199 72.6 %
Total 274 100 %
RESULTS OF IMMUNOHISTOCHEMICAL AND MOLECULAR
STUDIES
In this study, 71.7% expressed positive reaction for P53
(Table 13 & Chart 10)
Table 13: Distribution of P53 expression in Invasive Ductal
Carcinoma NOS
PARAMETER  POSTIVE  NEGATIVE
P 53 43(71.7%) 17(28.3%)
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CORRELATION OF P53 WITH OTHER PROGNOSTIC
FACTORS
P53 over expression was noted in 80% of premenopausal women
and 63.33% of postmenopausal women. The correlation between
menstrual status and p53 over expression was not significant. (Table 14&
Chart 11)
Table 14: Correlation of menstrual status with P53 expression
Menstrual
status
P53 positive
(%)
P53 negative
(%) Total
Pearson chi
square test
Premenopausal 24(80%) 6(20%) 30
 P=0.15
Postmenopausal 19(63.33%) 11(36.67%) 30
P53 expression was noted in 75% of T1 size tumors, 69.05% of T2
size tumors and 78.57% of T3 size tumors. No significant correlation was
found between the tumor size and P53 over expression (Table 15&
Chart 12).
Table 15: Correlation of tumor size and P53 expression
Average
size
P53 positive
(%)
P53 negative
(%) Total
Pearson chi
square test
<2 cm (T1) 3(75%) 1(25%) 4
 P=0.782 -5 cm (T2) 29(69.05%) 13(30.95%) 42
>5 cm (T3) 11(78.57%) 3(21.43%) 14
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P53 expression was noted in 68.75% of nodal metastasis positive
group as against 75% of nodal metastasis negative group. The correlation
between nodal metastasis and P53 over expression was not significant.
(Table 16 & Chart 13)
Table 16: Correlation of nodal metastasis and P53 expression
Nodal
metastasis
P53 positive
(%)
P53 negative
(%)
Total Pearson chisquare test
Present 22(68.75%) 10(31.25%) 32
 P=0.65
Absent 21(75%) 7(25%) 28
65% of  grade 1, 75% of grade 2 and 75% of grade 3 tumors were
found to be positive for P53 expression (Table 17& Chart 14).Thus, there
was an increase in the P53 expression with increasing grade of breast
cancer and the association was statistically significant(p=0.025).
Table 17: Correlation of grade and P53 expression
Grade P53 positive (%) P53 negative (%) Pearson chisquare test
Grade 1 13(65%)           7(35%) P =  0.18
Grade 2 15(75%) 5(25%) P = 0.025
Grade 3 15(75%) 5(25%) P = 0.025
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Table 18: Correlation of P53 with other histological prognostic
factors
Patient characteristics
P53 Pearson chi
square testNegative Positive
Skin infiltration Present 4 9  P=0.82
Absent 13 34
Lymphatic invasion Present 13 29  P=0.49
Absent 4 14
Vascular invasion Present 7 22  P=0.48
Absent 10 21
Lymphocytic infiltration Present 8 34  P=0.15
Absent 9 9
Necrosis Present 7 11  P=0.23
Absent 10 32
No significant correlation was noted between p53 expression and
other prognostic factors such as skin infiltration, lymphatic invasion,
vascular invasion, lymphocytic infiltration and necrosis as shown in
table 18.
EVALUATION OF E CADHERIN GENE MUTATION
            Mutation of E Cadherin gene, CDH1was analyzed for 25 cases of
invasive ductal carcinoma NOS by PCR and 60% of the cases showed
mutation (Table 19 & Chart 15).
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Table 19: Distribution of CDH1 gene mutation in  Invasive Ductal
Carcinoma NOS
PARAMETER MUTATION POSITIVE MUTATION NEGATIVE
CDH1 15(60%) 10(40%)
CORRELATION OF CDH1 GENE MUTATION WITH OTHER
KNOWN PROGNOSTIC FACTORS
CDH1 gene mutation was noted in 56.25 % of premenopausal
women and 66.67% of postmenopausal women. There was no significant
correlation between the menstrual status and CDH1 gene mutation.
(Table 20 & Chart 16)
Table 20: Correlation of menstrual status and CDH1 gene mutation
Menstrual
status
CDH1 mutation
positive (%)
CDH1 mutation
negative (%) Total
Pearson
chi square
test
Premenopausal 9(56.25%) 7(43.75%) 16
 P=0.61
Postmenopausal 6(66.67%) 3(33.33%) 9
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CDH1gene mutation was noted in 50% of T1 size tumors, 52.95%
of T2 size tumors and 83.33 % of T3 size tumours. There was no
significant correlation between the tumour size and CDH1gene mutation.
(Table 21 & Chart 17)
Table 21: Correlation of tumour size and CDH1 gene mutation
Average
size
CDH1 mutation
positive (%)
CDH1 mutation
negative (%) Total
Pearson
chi square
test
<2 cm (T1) 1(50%) 1(50%) 2
P=0.402 -5 cm (T2) 9(52.95%) 8(47.05%) 17
>5 cm (T3) 5(83.33%) 1(16.67%) 6
CDH1 gene mutation was noted in 66.67% of nodal metastasis
positive group as against 50% of nodal metastasis negative group. Thus,
there was an increase in the CDH1 gene mutation among the nodal
metastasis positive group but no significant correlation was found in
statistical analysis. (Table 22 & Chart 18)
Table 22: Correlation of nodal metastasis and CDH1 gene mutation
Nodal
metastasis
CDH1 mutation
positive (%)
CDH1 mutation
negative (%) Total
Pearson chi
square test
Present 10(66.67%) 5(33.33%) 15
P=0.49
Absent 5(50%) 5(50%) 10
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50% of  grade I, 53.3% of grade II and 83.3% of grade III tumours
were found to be positive for CDH1 gene mutation (Table 23 & Chart
19). Thus, there was an increase in the mutation in higher grade tumours
but the association was not found to be statistically significant.
Table 23: Correlation of grade and CDH1 gene mutation
Grade CDH1 mutationpositive (%)
CDH1 mutation
negative (%)
Pearson
chi square test
Grade 1 2(50%) 2(50%)
P=0.40Grade 2 8(53.3%) 7(46.67%)
Grade 3 5(83.3%) 1(16.67%)
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Table 24: Correlation of CDH1 gene mutation with other histological
prognostic factors
Patient characteristics
CDH1 Mutation Pearson chi
square testNegative Positive
Skin infiltration Present 2 3
P=1.00
Absent 8 12
Lymphatic invasion Present 8 12
P=1.00
Absent 2 3
Vascular invasion Present 7 10
P=0.86
Absent 3 5
Lymphocytic infiltration Present 10 12
P=0.13
Absent 0 3
Necrosis Present 1 3
P=0.50
Absent 9 12
There was no statistically significant association noted between
CDH1 gene mutation and other prognostic factors such as skin
infiltration, lymphatic invasion, vascular invasion, lymphocytic
infiltration and necrosis as shown in Table 24.
CORRELATION OF HOX D10 GENE EXPRESSION WITH
OTHER KNOWN PROGNOSTIC FACTORS
HoxD10 gene was downregulated in 46.67% of the cases. Table 25
and Chart 20 shows increased mean relative concentration of HoxD10
gene in premenopausal women as opposed to lesser relative concentration
in postmenopausal women. The correlation was not found to be
statistically significant.
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Table 25: Correlation of menstrual status and HoxD10 gene
expression
The mean relative concentration of HoxD10 mRNA was higher in
small size tumors when compared to large size tumors. The correlation
was not found to be statistically significant (Table 26 & Chart 21).
Table 26: Correlation of tumor size and HoxD10 gene expression
Size N
Mean relative
concentration of
HoxD10 mRNA
Standard
Deviation
Kruskal
Wallis
test
<2 cm 4 2.538 2.927
P=0.1452 to 5 cm 42 3.780 5.552
>5 cm 14 1.596 2.813
Menstrual
status N
Mean relative
concentration of
HoxD10 mRNA
Standard
Deviation T Test
Premenopausal 30 3.28 4.19
P=0.87
Postmenopausal 30 3.08 5.67
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The relative expression of HoxD10 mRNA was higher in patients
without axillary node metastasis but the correlation was not statistically
significant (Table 27& Chart 22).
Table 27: Correlation of nodal metastasis and HoxD10 gene
expression
Lymph
node
metastasis
N
Mean relative
concentration of
HoxD10 mRNA
Standard
Deviation
Mann
whitney U
test
Absent 28 3.491 4.953
P=0.415
Present 32 2.923 5.007
HoxD10 mRNA was found to be markedly downregulated in grade
3 tumors when compared to the other grades and the correlation was
statistically significant. (P=0.00) (Table 28& Chart 23)
Table 28: Correlation of grade and HoxD10 gene expression
Grade N
Mean relative
concentration of
HoxD10 mRNA
SD Kruskal Wallistest
1 20 3.368 5.697
P=0.002 20 6.141 4.898
3 20 0.054 0.058
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 No significant association was present between the HoxD10 gene
concentration and other prognostic factors such as skin infiltration,
lymphatic invasion, vascular invasion, lymphocytic infiltration and
necrosis (Table 29).
Table 29: Correlation of HoxD10 and other histological prognostic
factors
Tumour  characteristics N Mean SD Mann whitneyU test
Skin infiltration
Absent 47 3.24 4.77
P=0.26
Present 13 2.97 5.72
Lymphatic invasion
Absent 18 3.98 5.45
P=0.24
Present 42 2.84 4.74
Vascular invasion
Absent 31 3.01 4.37
P=0.67
Present 29 3.36 5.56
Lymphocytic
infiltration
Absent 18 2.86 4.39
P=0.94
Present 42 3.32 5.21
Necrosis
Absent 42 3.36 5.02
P=0.37
Present 18 2.77 4.87
CORRELATION BETWEEN P53 STATUS, CDH1 GENE
MUTATION & HOXD10 GENE EXPRESSION
The mean relative concentration of HoxD10 mRNA was higher in
P53 negative group when compared to P53 positive group (table 30&
Chart 24). However, the correlation was not statistically significant.
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Table 30: Correlation between P53 and HoxD10 gene expression
P53 N
Mean relative
concentration of
HoxD10 mRNA
SD
Mann
whitney U test
Positive 43 3.10 4.95 P=0.49
Negative 17 3.39 5.07
CDH1 gene mutation was found in 63.64% of p53 positive cases
and 33.33% of p53 negative cases (table 31& Chart 25). There was no
statistically significant association noted between CDH1 gene mutation
and p53 expression.
Table 31: Correlation of P53 and CDH1 gene mutation
CDH1 mutation
positive(%)
CDH1 mutation
negative(%)
Pearson chi
square test
P53 positive 14(63.64%) 8(36.36%)
      P=0.31P53 negative 1(33.33%) 2(66.67%)
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The mean relative concentration of HoxD10 mRNA was higher in
the CDHI gene mutation negative group (table 32& Chart 26). The
correlation was not statistically significant.
Table 32: Correlation between HoxD10 gene expression and CDH1
gene mutation
CDHI
mutation N
Mean relative
concentration of
HoxD10 mRNA
SD
Mann
whitney U
test
Positive 15 3.29 3.75 P=0.64
Negative 10 3.62 4.39
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DUCTAL CARCINOMA BREAST
Figure 3: Grey white firm mass with irregular margins
MUCINOUS CARCINOMA
Figure 4: Well circumscribed glistening gelatinous mass
930/12
9462/12
PAPILLARY CARCINOMA
Figure 5: Well circumscribed grey white mass with granular surface
APOCRINE CARCINOMA
Figure 6: Well circumscribed grey white mass with cystic degeneration and
hemorrhage
2638/11
1353/12
MEDULLARY CARCINOMA
Figure 7: Well circumscribed grey white fleshy mass
METAPLASTIC CARCINOMA
Figure 8: well circumscribed grey white firm mass
8213/12
9078/12
INVASIVE DUCTAL CARCINOMA NOS - GRADE 1
Figure 9: Invasive ductal carcinoma NOS
tubule formations >75% tumor cells (40X)
HPE 7495/11
Figure 10: Malignant ductal epithelial cells
with mild nuclear pleomorphism & low
mitosis HPE 7495/11 (400X)
INVASIVE DUCTAL CARCINOMA NOS GRADE 2
Figure 11: Sheets of malignant ductal
epithelial  cells, 30% tubule formation
HPE 9438/12(100X)
Figure 12: Malignant ductal epithelial cells
in sheets, 30% tubules and mild nuclear
pleomorphism  HPE 9438/12(400X)
INVASIVE DUCTAL CARCINOMA NOS - GRADE 3
Figure 13: Malignant ductal epithelial cells
in sheets HPE 948/12 (100X)
Figure 14: Malignant ductal epithelial cells
with no tubules, marked nuclear
pleomorphism, increased mitosis
HPE 948/12(400X)
MUCINOUS CARCINOMA
Figure 15: Tumor nests floating in mucin
HPE 7764/11(100X)
Figure 16: Malignant ductal epithelial
cells  with mild nuclear pleomorphism
and no mitosis HPE 7764/11 (400X)
LOBULAR CARCINOMA
Figure 17: Tumor cells arranged in
lobular pattern with pagetoid spread
around ductal elements
HPE 291/10 (100X)
Figure 18: Tumor cells arranged in
singles in Indian file pattern
HPE 291/10 (400X)
MEDULLARY CARCINOMA
Figure 19: Nodular arrangement of tumor
cells with lymphoplasmacytic infiltrate in
periphery HPE 8213/12 (100X)
Figure 20: Tumor cells in syncytial
pattern with marked nuclear
pleomorphism and prominent
nucleoli   HPE 8213/12 (400X)
PAPILLARY CARCINOMA
Figure 21: Tumor cells in papillary
pattern HPE 9053/12 (100X)
Figure 22: Tumor cells in delicate
papillary pattern  HPE 9053/12 (400X)
INVASIVE CRIBRIFORM CARCINOMA
Figure 23: Tumor cells in cribriform
pattern HPE 2375/12 (40X)
Figure 24: Malignant cells in cribriform
pattern with infiltration HPE 2375/12
(400X)
INVASIVE MICROPAPILLARY CARCINOMA
Figure25: Tumour cells in micropapillary
pattern with infiltration
HPE 2683/10 (100x)
Figure 26: Clusters of tumour cells lying
within clear stromal spaces  HPE 2683/10
(400X)
APOCRINE CARCINOMA
Figure 27: Apocrine cells in papillary
pattern HPE 6973/11(100X)
Figure 28: Apocrine cells with
abundant  granular eosinophilic
cytoplasm  (400X) HPE 6973/11
METAPLASTIC CARCINOMA WITH SQUAMOUS
DIFFERENTIATION
Figure 29: Nests of tumor cells with
squamous cell differentiation
HPE 5538/12 (100X)
Figure 30: Squamous cell nest in between
the tumour cells HPE 5538/12 (400X)
NEUROENDOCRINE CARCINOMA
Figure 31: Tumor cells in nests separated
by  fibrovascular septa HPE 1164/12
Figure 32: Uniform oval shaped tumor
cells with salt and pepper chromatin
HPE 1164/12
OTHER PROGNOSTIC FACTORS
Figure 33:Metastatic deposit in node
(100X) HPE 9235/12
Figure 34: Lymphatic invasion
HPE 5791/11
Figure 35: Vascular invasion (400X)
HPE 9053/12
Figure 36: Lymphocytic infiltration
(100X) HPE 8213/12
Figure 37: Necrosis : HPE 9413/10
(100X)
Figure 38: Skin infiltration: HPE 1947/11
(100X)
P53
Figure 39: Invasive ductal carcinoma NOS
Positive nuclear staining with p53
antibody  HPE: 4511/11
Figure 40: Invasive ductal carcinoma
NOS   negative for p53
HPE: 4555/11
65
DISCUSSION
Breast carcinoma is the most common cause of cancer related
mortality in urban Indian women and the second commonest cause in
rural women1.There is a gradual increase in the breast cancer incidence
worldwide. It accounts for about 23% of all cancers in women2.Early
detection and treatment can certainly reduce the mortality rates.
In the present study, immunohistochemical evaluation and genetic
analysis by PCR were done in 60 invasive ductal carcinoma cases and an
attempt has been made to evaluate p53, E Cadherin and HoxD10 status in
breast cancers and their correlation with histological grade and other
prognostic factors.
Madras Medical College being a tertiary referral centre, the relative
frequency of breast cancers among the other surgical cases was 2.04%.
Among the entire breast specimens received for histopathological
examination, 33.82% of the cases were reported to be malignant.
The age of breast cancer patients ranged from 25 to 85 years with a
mean age of 50.7 years. The highest incidence of breast cancer occurred
in 41 to 50 year age group. This is in concurrence with the study done by
Rajesh Singh Laishram et al.90
66
The most common histological subtype of breast cancer in this
study is Invasive ductal carcinoma NOS type. This is similar to the study
of Albrektsen et al,91 Shirley  SE  et  al92 and AM Dauda et al93. The
incidence of invasive ductal carcinoma NOS type is higher in Indian
population (89.8%) than that of western population accounting for the
worse prognosis (Table 33).
Table 33: Comparison of distribution of histological subtypes of
breast cancers
Histological subtypes AM Daudaet al93
Shirley SE
et al92
Albrektsen
et al91
Current
study
Invasive ductal carcinoma
NOS 78.8% 69.3% 81.4% 89.8%
Lobular carcinoma 6.7% 5.6% 6.3 % 0.7%
Tubulolobular carcinoma - 0.5% - -
Mixed carcinoma - - - 0.4%
Mucinous carcinoma 2.4% 3.6% 2% 1.8%
Micropapillary carcinoma - 0.5% - 0.7%
Microinvasive carcinoma - 0.3% - -
Papillary carcinoma 4.2% 3.5% - 1.5%
Metaplastic carcinoma 2.4% 1.3 - 1.5%
Tubular carcinoma - 0.8% 2% -
Cribriform carcinoma - 0.1% - 0.4%
Medullary carcinoma 3.6% 1% 1.1% 0.7%
Apocrine carcinoma - - - 1.5%
Adenoid cystic carcinoma - 0.1% - 0.42%
Malignant phyllodes 1.8% - 0.4% 0.7%
Neuroendocrine carcinoma - - - 0.4%
Inflammatory carcinoma - 1.4% - -
Other specific types - - 1.2% -
Adenocarinomas
unspecific - 5.3% 5.5% -
DCIS - 7.1% - -
Paget’s disease - 0.1% 1.5% -
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In the study done by Zeeshan Butt et al, breast cancer incidence
was 42.7% in pre-menopausal and 57.3% in post-menopausal women.94
In the current study, the incidence of breast cancer among pre and post-
menopausal women were 56.6% and 43.4% respectively. 0.7% of the
total breast cancers were reported in males. 48.5% of the breast cancers
were present in left breast, 51.5% in right breast and 1 case was found to
have bilateral breast cancer.
Table 34: Comparison of distribution of AJCC staging in breast
cancers
Stage Hong SukSon et al95
Rajesh Singh
Laishram et al90
Carey
et al96
Current
study
Stage I 24.3 3.37 39 6.93
Stage II 70.3 12.36 51 43.8
Stage III 5.4 76.4 8 48.18
Stage IV NA 7.87 3 1.09
Most of the cases presented in stage III followed by stage II which
was  similar  to  that  of  Rajesh  Singh  Laishram  et  al90 who studied 142
breast cancers in Manipur and reported the increased incidence of higher
stage tumors in their population when compared to the western studies
done by Hong Suk Son et al95 and Carey et al96 (Table 34).
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A higher proportion of T2 sized tumors (59.12 %) were seen
(Table 35) similar  to the study of Christine L.  Carter  et  al  (USA),97 and
Lakmini et al (India).99
Table 35: Comparison of size of tumors
Size Christine  L.Carter et al97
F S Al-Joudi
et al98
Lakmini
et al99
Current
study
T1 33.6 3.14 14.5 17.16%
T2 55.4 19.37 74 59.12%
T3 11 77.49 11.5 23.72%
The Grade II tumors were more frequent than other grades of
breast cancers. This observation was similar to the study carried out by
Qiu J et al100, Carey et al96 and GG Van den Eynden et al101 (Table 36).
Table 36: Comparison of grade of tumor
Grade Qiu Jet al100
Carey
et al96
GG Van den
Eynden et al101
Current
study
Grade I 33.3% 25% 32.63% 28.1%
Grade II 54% 26% 36.84% 46.7%
Grade III 12.7% 49% 30.53% 14.6%
Nodal metastasis was noted in 52.6 % of the cases while it was not
seen  in  47.4%.  This  result  correlates  with  the  study  done  by  Jun   Qiu
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et al100 and  SE Shirley  et  al92 who reported nodal metastasis in 60.32%
and 75.7% of their cases.
66.4% of cases had lymphatic invasion and 37.2% of the cases had
vascular invasion which was similar to the observation made by GG Van
den Eynden et al101, who reported 69.5% lymphatic invasion and 37.9%
vascular invasion in his study.
There were lymphocytic infiltration in 58.4%, skin infiltration in
19% and necrosis in 27.4% of the cases, in concurrence to the 33% skin
infiltration reported in the study conducted by Chanda Bewtra et al102 and
38.1% necrosis in the study conducted by Gloria Perio et al.103
TABLE 37 COMPARISON OF P53 EXPRESSION IN
WORLD STATISTICS
P53 positive (%)
Iwaya K et al89 21.4
Hong Suk Song et al95 51.6
F S Al-Joudi et al 98 29.6
Barbareschi M et al104 17
Zainab W. Aziz105 38.3
M.Etebary et al106 40.3
Current study 71.7
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CORRELATION OF P53 EXPRESSION WITH OTHER KNOWN
CLINICOPATHOLOGICAL PROGNOSTIC FACTORS
Mattia Barbareschi et al (1996) studied 178 breast cancer patients
in Italy and found direct statistically significant relationship between p53
expression and lower age, greater tumour size, ductal morphology, higher
grade and ER negative status.104
M.Etebary et al (2002) studied the P53 expression in 72 Iranian
breast cancer patients and reported statistically significant direct
association between p53 expression and high tumour grade, age at
diagnosis above 45 years. He reported that p53 overexpression can be
considered as a marker of increased malignant potential in breast cancers
and accounts for poor prognosis.106
Hong Suk Song (2006) et al studied p53 expression in 440 Korean
breast cancer patients. The p53 overexpression inversely correlated with
lymph node metastasis. The tumor size, histological type, grade, hormone
receptor  status  and  stage  of  the  tumour  were  not  related  to  the  p53
overexpression.95
F S Al-Joudi et al (2008) studied p53 expression in 382 breast
cancer patients in Malaysia. P53 expression showed significant
association with the age and histological grade of the tumour. No
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significant association was noted with nodal status, tumour size, side of
the tumour and ER & PR expression.98
Zainab W. Aziz et al (2011) studied p53 expression in 60 breast
cancer patients in Mosul city.Over expression of P53 showed significant
correlation with patient's age, tumour grade, stage, and size, but no
correlation was found with menopausal status and axillary lymph node
metastasis.105
        In comparison with the above mentioned studies, the present study
showed significant correlation between p53 expression and higher
histological grade. The correlation with other clinicopathological
variables was not significant.
Table 38: Comparison of CDH1 gene inactivation in world statistics
CDH1 gene inactivation (%)
Shohreh A. Shargh et al107 94
Celebiler Cavusoglu A et al15 33.9
Caldeira José Roberto F et al108 72
Masaru Shinozaki et al109 53
Mozhgan Rasti et al110 41
Current study 60
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CORRELATION OF E CADHERIN GENE MUTATION WITH
OTHER KNOWN CLINICOPATHOLOGICAL PROGNOSTIC
FACTORS
C Parker et al (2001) studied E Cadherin expression by IHC in 174
breast cancer patients from the Nottingham breast cancer series.
Significant correlation was found between E Cadherin expression and
histological type, grade and ER status. No significant association was
found with tumour recurrence, distant metastases, lymph node status,
vascular invasion, tumour size and survival.111
          Masaru Shinozaki et al (2005) studied 151 breast cancer patients in
California and found that hypermethylation of the CDH1 gene was
significantly associated with primary breast tumors demonstrating
lymphovascular invasion, infiltrating ductal histology, negativity for the
oestrogen receptor and also was frequently associated with sentinel
lymph node metastasis.109
Anca Botezatu et al (2008) studied 25 breast cancer patients in
Romania and found that epigenetic silencing of E Cadherin gene is
associated with high mitotic activity, poorer tumour differentiation, and
increased tendency for regional lymph node metastases.112
Mozhgan Rasti et al (2009) studied 67 Iranian breast cancer
patients and found that there was a significant correlation between
73
hypermethylation  of  CDH1  locus  and  tumour  size   ? 5  cm.  The
association with other clinicopathological parameters like age,
histological type, grade, nodal involvement, ER & PR status were not
found to be significant.110
Celebiler Cavusoglu A et al (2010) studied 62 breast cancer
patients from Turkey and found that CDH1 under expression showed
significant association with advanced tumour stage, histological type,
higher tumour grade and lymph node metastasis.15
Shohreh A. Shargh et al (2011)  studied 50 breast cancer patients in
Iran and found significant association between CDH1 gene mutation and
higher tumour grade, stage and tumour metastasis.107
     In the present study the correlation between CDH1 gene mutation and
other clinicopathological parameters were not found to be significant.
CORRELATION OF HOX D10 GENE EXPRESSION WITH
OTHER CLINICOPATHOLOGICAL PROGNOSTIC FACTORS
Kokonoe Makiyama et al (2004) studied 18 breast cancer patients
in Japan and found that there was a significant down regulation of the
HoxD10 gene in cancerous tissue compared to non cancerous tissue.
There was no significant correlation between age, menopausal status,
tumour size, serum CEA and CA 125 levels.19
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Meritxell Carrio et al (2005) analysed HoxD10 gene in human
breast epithelial cell cultures by PCR. Strong expression of HoxD10 was
found in premalignant epithelial cells, but the expression was largely
absent in invasive breast carcinomas. They also showed that when
HoxD10 was re-introduced in breast cancer cells using retroviral genetic
transfer, cell migration was impaired and there was restoration of normal
cellular polarisation with acinar morphology.86
Li Ma et al ( 2007) showed by cell culture studies that inhibition of
HoxD10 by miR-10b, resulted in increased expression of pro metastatic
gene RHOC leading to tumour invasion and metastasis.113
Sirigiri Divijendra Natha Reddy et al (2008) demonstrated by cell
culture studies using PCR that HoxD10 is a positive regulator of miR-7,
the loss of which results in increased Pak1 expression and leads to
increased motility, invasiveness, anchorage-independent growth and
breast cancer progression from low to highly invasive phenotypes.87
Connie Myers et al (2002) studied HoxD10 expression in
endothelial  cell  cultures  by  PCR.  Their  study  showed that  HoxD10 was
highly expressed in quiescent endothelial cells, but the expression
decreases in angiogenic vessels in the tumour microenvironment and that
sustained HoxD10 expression can inhibit angiogenesis in vivo.114
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SUMMARY
60 breast cancer samples were subjected to immunohistochemistry
and polymerase chain reaction to evaluate the p53, HoxD10 and E
Cadherin status and the results were correlated with histological grade
and other known clinicopathological prognostic factors. The relative
frequency of breast carcinoma among other surgical cases of Madras
Medical College is 2.04%.
? The non neoplastic breast lesions form 29.9%, benign tumors
36.28% and malignant tumors 33.82%.
? Breast carcinoma had the highest incidence in the 41 to 50 year age
group.
? The most common histological subtype was Invasive ductal
carcinoma NOS type which constituted 89.8%.
? 69%  of  the  breast  cancer  presented  with  T2  size  (2  to  5  cm)
tumours.
? Grade II was the most common grade observed accounting for
52.24%.
? Nodal metastasis was observed in 52.6 %.
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? Lymphatic invasion and vascular invasion were seen in 66.4% and
37.2% respectively.
? Skin infiltration was seen in 19% of the tumours.
? Lymphocytic infiltration was observed in 58.4% of the tumours.
? Necrosis was found in 27.4% of the tumours.
? p53 expression was seen in 71.7% of the tumours.
? p53 over expression showed statistically significant association
with high grade tumours.
? An increase in the number of cases with p53 positivity was seen
with increasing tumour size and cases with lymphovascular
invasion.
? No statistically significant association was found between p53
expression and age, nodal status, skin infiltration, lymphocytic
infiltration or necrosis.
? HoxD10 gene was down regulated in 46.67% of the tumours.
? HoxD10 gene down regulation showed statistically significant
association with grade III tumours.
? The relative expression of HoxD10 gene was lower among
postmenopausal women, tumours with larger size, positive nodal
status, skin infiltration, lymphatic infiltration and necrosis.
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? No association was found between HoxD10 gene expression and
vascular invasion and lymphocytic infiltration.
? CDH1 gene mutation was seen in 60% of the tumours.
? CDH1 gene mutation was more frequent among postmenopausal
women, tumours with increasing size, grade, nodal status and
lymphovascular invasion. However, the association was not
statistically significant.
? No association was found between CDH1 gene mutation and other
prognostic factors like skin infiltration, lymphocytic infiltration
and necrosis.
? The mean relative concentration of HoxD10 mRNA was lower in
the p53 positive group when compared to P53 negative group.
However, the correlation was not statistically significant.
? The mean relative concentration of HoxD10 mRNA was lower in
the CDHI gene mutation positive group. The correlation was not
statistically significant.
? CDH1 gene mutation was found to be more common among the
p53 positive cases than the p53 negative cases. But, there was no
statistically significant association noted between CDH1 gene
mutation and p53 expression.
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CONCLUSION
The incidence of Invasive ductal carcinoma NOS was higher in this
study. Many of our patients presented in younger age with large sized
tumors accounting for aggressive nature of breast cancer in our
population.P53 over expression and HoxD10 gene down regulation
showed significant association with higher grade tumours. This suggests
that p53 and HoxD10 gene play an important tumour suppressor role and
the loss of which results in breast cancer progression.
          The current study shows that E Cadherin gene mutation occurs
with high frequency in invasive ductal carcinoma. Although not
statistically significant, E Cadherin gene mutation was found to be more
common in higher grade tumours. This could be due to the small size of
the study sample and investigation in larger series is essential to evaluate
its prognostic value.
          In conclusion, molecular analysis of breast carcinoma may serve as
an important prognostic tool to predict patient outcome and for the
development of targeted therapy in this new era of early cancer detection.
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ANNEXURE – I
PROFORMA
Case number : Name :
HPE number : Age :
IP number : Sex :
Clinical diagnosis : Menstrual status :
Risk factors if any :
Side of breast : Right/Left
Specimen : Simple Mastectomy / Modified radical
mastectomy / Radical Mastectomy / Toilet
mastectomy / Others
GROSS
Specimen size :
Nipple areola : Skin  :
Tumor size : Tumor margin:
Appearance :
Resected margis : Superior : Inferior :
Medial : Lateral  :
Posterior :
Associated findings  :
Total number of nodes dissected :
Largest node size :
MICROSCOPY
Histological subtype :
Histological score: Nuclear score: Mitotic score:
Modified Scarff  Bloom Richardson Grade :  I / II /  III
Skin : Free /   Involved
Nipple & Areola : Free /   Involved
Margins : Superior : Free /  Involved
Inferior   : Free /   Involved
Medial    : Free /   Involved
Lateral    : Free /   Involved
Posterior : Free /   Involved
Lymphatic invasion: Present   /   Absent
Vascular invasion :           Present    /    Absent
Lymphocytic infiltration:           Present    / Absent
Necrosis :           Present    / Absent
Associated breast lesions :
Total number of nodes dissected:
Number of nodes involved :
P53 status :      positive   /   negative
CDH1 mutation status :     positive   /   negative
Relative expression of  Hox D10 in relation to ACTB1 gene:
ANNEXURE II
WHO HISTOLOGICAL CLASSIFICATION OF EPITHELIAL BREAST
TUMORS
INVASIVE BREAST CANCERS NON INVASIVE BREAST CANCERS
Invasive ductal carcinoma not otherwise specified    Ductal carcinoma in situ
    Mixed type carcinoma    Lobular carcinoma in situ
    Pleomorphic carcinoma   Atypical papilloma
    Carcinoma with osteoclastic type of giant cells
    Carcinoma with choriocarcinomatous features BENIGN EPITHELIAL TUMORS
    Carcinoma with melanotic features
Invasive lobular carcinoma Tubular adenoma
Tubular carcinoma Lactating adenoma
Invasive cribriform carcinoma Apocrine adenoma
Medullary carcinoma Pleomorphic adenoma
Mucinous carcinoma Ductal adenoma
Cystadenocarcinoma Papilloma
Signet ring carcinoma
Neuroendocrine tumors FIBROEPITHELIAL TUMORS
    Solid neuroendocrine carcinoma Fibroadenoma
    Atypical carcinoid tumor Phyllodes tumor
    Small cell/oat cell carcinoma        Benign
    Large cell neuroendocrine carcinoma        Borderline
Invasive papillary carcinoma        Malignant
Invasive micropapillary carcinoma Periductal stromal sarcoma
Metaplastic carcinoma Mammary hamartoma
Apocrine carcinoma
Pure epithelial metaplastic carcinoma
Squamous cell carcinoma
Adenocarcinoma with spindle cell metaplasia INTRADUCTAL
Adenosquamous carcinoma PROLIFERATIVE
Mucoepidermoid carcinoma LESIONS
Mixed epithelial/mesenchymal metaplastic carcinoma    Atypical ductal hyperplasia
Lipid rich carcinoma        Flat epithelial atypia
Secretory carcinoma        Usual epithelial hyperplasia
Oncocytic carcinoma
Adenoid cystic carcinoma METASTATIC TUMORS
Acinic cell carcinoma
Glycogen rich carcinoma
Sebaceous carcinoma
Inflammatory carcinoma
Intraductal papillary carcinoma
Intracystic papillary carcinoma
Microinvasive carcinoma
ANNEXURE III
NOTTINGHAM MODIFICATION OF SCARFF BLOOM
RICHARDSON GRADING SYSTEM
TUBULE FORMATION SCORE
Tubule formation in >75% of the tumor 1
Tubule formation in 10 to 75% of the tumor 2
Tubule formation in <10 % of the tumor 3
NUCLEAR PLEOMORPHISM SCORE
Minimal variation in size and shape of nuclei 1
Moderate variation in size and shape of nuclei 2
Marked variation in size and shape of the nuclei 3
MITOTIC RATE SCORE
<10 Mitosis per 10 high power field 1
10 to 20 mitosis per 10 high power field 2
>20 mitosis per 10 high power field 3
GRADE SCORE
Grade 1 3,4,5
Grade 2 6,7
Grade 3 8,9
ANNEXURE IV
IMMUNOHISTOCHEMISTRY PROCEDURE
1. 4µ thick sections were cut from formalin fixed paraffin embedded tissue
samples and transferred to gelatin-chrome alum coated slides.
2. The slides were incubated at 58ºC for overnight.
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes.
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2
changes.
5. The sections were washed in tap water for 10 minutes.
6. The slides were then immersed in distilled water for 5 minutes.
7. Heat induced antigen retrieval was done with microwave oven in
appropriate temperature with appropriate buffer for 20 to 25 minutes.
8. The slides were then cooled to room temperature and washed in running
tap water for 5 minutes.
9. The slides were then rinsed in distilled water for 5 minutes.
10. Wash with appropriate wash buffer (phosphate buffer) for 5 minutes x 2
changes.
11. Apply peroxidase block over the sections for 10 minutes.
12. Wash the slides in phosphate buffer for 5 minutes x 2 changes.
13. Cover the sections with power block for 15 minutes.
14. The sections were drained (without washing) and appropriate primary
antibody was applied over the sections and incubated for 45 minutes.
15. The slides were washed in phosphate buffer for 5 minutes x 2 changes.
16. The slides were covered with Super Enhancer for 30 minutes.
17. The slides were washed in phosphate buffer for 5 minutes x 2 changes.
18. The slides were covered with SS Label for 30 minutes.
19. Wash in phosphate buffer for 5 minutes x 2 changes.
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1
ml of DAB buffer.
21. DAB substrate solution was applied on the sections for 8 minutes.
22. Wash with phosphate buffer solution for 5 minutes x 2 changes.
23. The slides are washed well in running tap water for 5 minutes.
24.  The sections were counterstained with Hematoxylin stain for 2 seconds
(1 dip).
25. The slides are washed in running tap water for 3 minutes.
26. The slides are air dried, cleared with xylene and mounted with DPX.
ANNEXURE V
RNA EXTRACTION
1. 10 Sections of formalin fixed paraffin embedded tissue samples with 10
µ thickness were collected in micro centrifuge tube.
2. Sections were cleared with 1 ml xylene, vortex, centrifuged for 2
minutes and supernatant was removed.
3. Sections were dehydrated with absolute ethyl alcohol, vortex,
centrifuged for 2 minutes and supernatant was removed.
4. The air dried tissue pellet was resuspended in 240 µl Buffer PKD &
10µl proteinase K mixture to reverse the formaldehyde modification of
nucleic acid.
5. Incubate the centrifuge tube at 55ºC for 15 minutes and 80ºC for 15
minutes.
6. 500µ of Buffer RBC was added to the mixture and vortex to adjust the
binding condition.
7. All the centrifuge tube contents were transferred to gDNA eliminator
spin column placed in 2 ml collection tube.
8. The tube is centrifuged at 13,000 rpm for 30 sec to filter the genomic
DNA in the tissue sample.
9. The column with genomic DNA was discarded and the flow through
was saved.
10. 1200ml of 100% ethanol was added to the flow through and mixed well
to enable precipitation of RNA in sample.
11. RNA precipitates were then filtered in RNeasy Minelute spin column
placed in 2 ml collection tube by centrifuging at 13,000 rpm for 15
seconds.
12. The column with RNA precipitate was transferred to another collection
tube and 500 µl of Buffer RPE  added and centrifuged at 13,000 rpm for
15 seconds and then the flow through was discarded.
13. Step 12 is repeated for 2 minutes.
14. Transfer RNeasy Minelute spin column to a new 2 ml collection tube
and centrifuged at 13,000 rpm for 5 minutes with their lids open to
remove the residual ethanol form RNA and the flow through was
discarded.
15. Transfer RNeasy Minelute spin column to a new 1.5 ml collection tube
and 30 µl of RNAse free water was added and centrifuged for 1 minute
at 13,000 rpm to elute total RNA.
16. The total RNA was stored at -20ºC to -70ºC.
KEY TO MASTER CHART
SI - Skin infiltration
LI - Lymphatic invasion
VI - Vascular invasion
LCI - Lymphocytic infiltration
NEC - necrosis
LNS - lymph node status
P53 -  Protein 53
HoxD10   - Relative Homeobox D10 gene expression in relation
to actin B-1 gene
CDH1 -  Cadherin-1
MRM - Modified radical mastectomy
SM - Simple mastectomy
RM - Radical mastectomy
TM - Toilet mastectomy
PSM - Palliative simple mastectomy
A - Absent
N - Negative
P - Present / positive
M - Male
F - Female
R - Right
L - Left
NAC - neoadjuvant chemotherapy
IDC NOS - Invasive ductal carcinoma not otherwise specified
Sup - superior
Inf - inferior
Med - medial
Lat - lateral
Post - posterior
G - Grade
S.NO. BIOPSY
NO
AGE SEX SIDE STAGE SURGERY SUBTYPE SIZE GRADE SI LI VI LCI NEC MARGINS LNS P53 HOX
D10
CDH1
MUTATION
1 37/10 75 F R IIB MRM IDC -COMEDO 6 3 A P P P P POST 0
2 67/10 70 F R IIA MRM IDC -PAPILLARY 2.5 A P P A A FREE 0
3 71/10 65 F L IIA MRM MUCINOUS CARCINOMA 5 A A P A A POST 0
4 150/10 45 F L IIIB PSM  LOBULAR CA 3 P P A A A FREE 0
5 238/10 74 F R IIIC TM IDC - COMEDO 7 3 A P P A P POST,MED,LAT 6
6 268/10 50 F R IIB MRM IDC - NOS 3.5 2 A P A P A FREE 1
7 281/10 39 F R IIA MRM IDC - NOS 5 3 A A A A P FREE 0
8 291/10 35 F R IIIC MRM LOBULAR CA 5 A P A P A POST 7
9 300/10 65 F R IIIC MRM IDC - NOS 7 3 A P A A A POST 8
10 349/10 63 F R IIIA MRM IDC - COMEDO 11 3 A P P P P FREE 12
11 354/10 60 F R IIIC MRM IDC- MICROPAPILLARY 8 A P P P A POST 5
12 367/10 55 F R IIIC MRM IDC - NOS 8 3 A P P P P POST 7
13 442/10 40 F L IIA MRM IDC - NOS 3.5 3 A P P P A FREE 0
14 523/10 42 F L IIIA MRM IDC -NOS 2 2 A P P P A FREE 3
15 544/10 35 F L IIIA MRM IDC - NOS 5.5 2 A P P P A POST 14
16 590/10 55 F R IIIA MRM IDC - NOS 2 1 A P P A A FREE 5
17 599/10 42 F R IIIB SM IDC- MUCINOUS 7 P P A P A LAT 0
18 673/10 35 F R IIA NAC + MRM IDC - NOS 3 1 A A A A A POST 0
19 698/10 60 F R IIA MRM IDC - COMEDO 4.5 3 A A A P P POST 0
20 705/10 50 F L IIB MRM IDC - COMEDO 3 3 A P A P P FREE 1
21 733/10 65 F R IIIA NAC + MRM IDC - NOS 3.5 2 A P A A A FREE 3
22 803/10 55 F L IIIA MRM IDC - NOS 6 1 A P A A P POST,MED 1
23 1031/10 65 F L IIIC MRM IDC - NOS 3.5 1 A P A A A POST 8
24 1123/10 43 F R IIB MRM IDC - NOS 4 1 A P A A A FREE 1
25 1192/10 50 F R IIIB TM IDC -NOS 5 2 P P A A A FREE 3
26 1234/10 69 M L IIIB MRM IDC - NOS 3 2 P P A A A POST 3
27 1285/10 55 F R IIIC MRM IDC - NOS 4 1 A P A A A POST 4
28 1315/10 40 F L IIIB MRM IDC - NOS 5 2 P P A P A FREE 1
29 1469/10 43 F R IIA MRM IDC - CRIBRIFORM 4.5 A A P P A FREE 0
30 1545/10 60 F R IIIA MRM IDC - NOS 1.5 2 A P P A A FREE 3
MASTER CHART
31 1597/10 73 F R IIA MRM IDC- MUCINOUS 5 A A A A A FREE 0
32 1632/10 50 F R IIIB NAC + MRM IDC -NOS 4 2 P P P P A FREE 2
33 1675/10 56 F R IIIA MRM IDC - NOS 5 2 A P P P A FREE 4
34 1695/10 40 F L IIIA MRM IDC - NOS 3 1 A A A P A POST 0
35 1731/10 50 F L IIB MRM IDC - NOS 3 3 P P P P A FREE 0
36 1738/10 50 F R IIIC MRM IDC - NOS 10 3 A P A P A POST 8 P 0.001
37 1776/10 26 F R IIA MRM IDC - NOS 5 1 A A A A A FREE 0
38 1852/10 35 F R IIIA MRM IDC - NOS 10 2 A P A P A FREE 1
39 1859/10 60 F R IIIC MRM IDC - NOS 3.5 1 A P A P A FREE 11
40 2077/10 53 F R IIA MRM IDC - NOS 3.5 2 A A P P A FREE 0
41 2144/10 74 F L IIIA MRM IDC - NOS 2 2 A P A A P FREE 3
42 2401/10 25 F L IIIC MRM IDC - NOS 3 1 A P A P P FREE 0
43 2589/10 45 F L IIA MRM IDC - COMEDO 3 3 A P A P P POST 0
44 2640/10 42 F L IIIA MRM IDC - NOS 2 1 A P A P A FREE 0
45 2683/10 42 F L IIA MRM IDC - MICROPAPILLARY 4 A P A P A FREE 0
46 2703/10 47 F R IIB MRM IDC - NOS 5 2 A P A P A FREE 1
47 2757/10 65 F L IIA MRM IDC - NOS 1.75 2 A P A A A FREE 1
48 2780/10 46 F L IIIA MRM IDC - COMEDO 8 3 A P A A P FREE 2
49 2795/10 42 F L IIA NAC + MRM IDC - COMEDO 5 3 A A A A P POST 0
50 2870/10 38 F L IIB MRM IDC - MEDULLARY 6 A A A P P FREE 0
51 2909/10 55 F R I MRM IDC - NOS 2 2 A A A P A POST 0
52 2933/10 40 F R IIIA MRM IDC - NOS 8 2 A P A P A POST 1
53 3103/10 40 F R IIIB MRM IDC - NOS 2.5 2 P A A P A FREE 1
54 3162/10 58 F L IIIC MRM IDC - NOS 5 2 P P A P A POST 6
55 3357/10 50 F R IIA MRM IDC - NOS 2.5 2 A P A A A FREE 0
56 3582/10 50 F L IV TM IDC - NOS 18 2 P P A A P POST 7
57 3598/10 35 F L I MRM IDC - NOS 2 2 A A A P P POST 0
58 3694/10 65 F R IIA TM IDC - NOS 5 3 A P P P A POST 0 P 0.093
59 3822/10 43 F L IIIA MRM IDCNOS 7.5 2 A P P P P POST 3
60 4090/10 55 F L IIIC MRM IDCNOS 2 3 A P P A A FREE 7
61 4125/10 47 F R IIIA MRM IDCNOS 8 3 A P A A A FREE 25
62 4570/10 36 F L IIIC MRM IDCNOS 7 2 A P A A A POST 7
63 4608/10 50 F L IIB NAC + MRM IDCNOS 3 2 A P A A A FREE 1
64 4637/10 53 F R IIIA MRM COMBINED 5 A P P P P FREE 6
65 4651/10 38 F R IIIB MRM IDCNOS 5 2 A P A P A POST 1
66 4660/10 37 F L I MRM IDCNOS 1 2 A A A P A FREE 0
67 4756/10 75 F L I MRM IDCNOS 2 1 A A A P A POST 0
68 4899/10 50 F L IIIC MRM IDCNOS 8 1 A P A P A FREE 5
69 4905/10 50 F R IIIC NAC + MRM IDCNOS 3.5 1 A P A A P FREE 4
70 4957/10 60 F L IIIB MRM IDCNOS 2.5 2 P P A A A FREE 2
71 5005/10 39 F L IIA MRM IDCNOS 2.5 1 A P P A P FREE 0
72 5162/10 47 F R IIIC MRM IDCNOS 3.5 2 A P A A A FREE 5
73 5222/10 45 F R IIIC MRM IDCNOS 1.5 2 A P P P P FREE 5
74 5297/10 43 F L IIB MRM IDCNOS 9 2 A A A A A FREE 0
75 5299/10 55 F R IIIA NAC +MRM IDCNOS 2.5 2 A P A A A FREE 10
76 5432/10 60 F R IIIC MRM IDCNOS 4.5 3 A P A P P POST 6 N 0.021
77 5509/10 38 F L IIIA MRM IDCNOS 3 2 A P A P A FREE 4
78 5525/10 56 F R IIB MRM METAPLASTIC CA 6 A A P A P FREE 0
79 5737/10 60 F R IIIA MRM IDCNOS 5 1 A P A P A FREE 21
80 5816/10 35 F L IIB MRM MAL PHYLLODES 10 A A A A P FREE 0
81 5875/10 60 F R IIA SM PAPILLARY CA 4 A A A A A FREE 0
82 6011/10 48 F R IIA MRM IDC - NOS 3 2 A A A A A FREE 0
83 6315/10 70 F L IIIB MRM IDC - NOS 3 1 P P A P A POST 1
84 6354/10 47 F R IIA MRM IDC - NOS 3 1 A A A A A FREE 0
85 6412/10 48 F R IIIB NAC + MRM IDCNOS 5 2 P P P P P FREE 2
86 6493/10 45 F R IIB MRM IDCNOS 4 1 A P A P P FREE 1
87 6520/10 38 F L IIIA MRM IDCNOS 8 3 A P A P P POST 10
88 6626/10 45 F R IIB MRM IDCNOS 17 2 A A A A A POST 0
89 6688/10 54 F R IIB MRM IDCNOS 4 1 A P A A A FREE 1
90 6791/10 70 F R IIB MRM  APOCRINE CA 7 A A A P P FREE 0
91 6952/10 50 F L IIIB TM IDCNOS 24 2 P A A A P FREE 0
92 6964/10 56 F R IIB MRM APOCRINE CA 5 A P A A A FREE 2
93 7033/10 55 F R IIB MRM IDCNOS 4 3 A P A A P FREE 2 N 0.085
94 7073/10 50 F L IIA MRM IDCNOS 3 1 A A A P A FREE 0
95 7110/10 75 F L IIIC MRM IDCNOS 4.5 1 A P A A A FREE 7 P 0.016
96 7141/10 48 F L IIA NAC + MRM IDCNOS 4 1 A A A P P FREE 0
97 7142/10 50 F R IIB NAC+ MRM IDCNOS 8 1 A A A A A FREE 0
98 7270/10 32 F R IIA MRM IDCNOS 4 1 A A A P A FREE 0
99 7331/10 37 F L IIIC MRM IDC - NOS 4 1 A P A A P POST 5 N 0.321
100 7459/10 68 F L IIA MRM IDC - NOS 3 1 A A A P P FREE 0
101 7538/10 48 F R IIIC NAC + MRM IDC - NOS 10 2 P P A A A FREE 6
102 7612/10 47 F R IIA MRM IDC - NOS 4 2 A A A A P FREE 0
103 7912/10 40 F L IIIB NAC + MRM IDC - NOS 4 2 P A A A P FREE 0
104 7934/10 57 F R IIA MRM IDC - NOS 2.5 1 A A A A P FREE 0 P 12.32
105 7961/10 70 F L IIB MRM IDC - NOS 8 1 A P A A P FREE 0
106 8176/10 65 F L IIA MRM IDC - NOS 3 1 A A A A A FREE 0
107 8197/10 56 F L IIA MRM IDC - NOS 3 2 A A A A P FREE 0
108 8391/10 40 F L IIB MRM IDC - NOS 4 1 A P A A P FREE 2
109 8440/10 43 F L IIIA MRM IDC - NOS 2 1 A P P A A POST 8
110 8440/10 43 F R I MRM IDC - NOS 2 1 A A A A A FREE 0
111 8449/10 64 F L I MRM IDC - NOS 2 2 A A A A P FREE 0
112 8519/10 63 F L IIIC NAC + MRM IDC - NOS 1 1 P P A A A FREE 6
113 8666/10 50 F L IIA MRM IDC - NOS 3 1 A A A A A FREE 0
114 8781/10 52 F L IIIB NAC + MRM IDC - NOS 3 1 A P A A A POST 2 P 2.06
115 8812/10 65 F R IIA MRM IDC - NOS 3 2 A P A A A FREE 0
116 9043/10 58 F L IIA SM IDC - NOS 3 2 A A A P A FREE 0
117 9053/10 52 F R IIIB TM IDC - NOS 8 3 P P P A P POST 0 P 0.001
118 9060/10 55 F R IIIC NAC+TM IDC - NOS 4 1 A P A A A FREE 4 N 1.563
119 9065/10 60 F L IIIA MRM IDC - NOS 2 2 A P A A P FREE 3
120 9078/10 60 F L IIIA MRM IDC - NOS 7 2 A P A P A FREE 3
121 9110/10 45 F L IIA MRM IDC - NOS 4 2 A A A P A FREE 0
122 9361/10 52 F L IIB MRM IDC - NOS 6 2 A A A A P FREE 0
123 9404/10 65 F L IIA NAC + MRM PAPILLARY CA 4 A A A A A FREE 0 P 0.21
124 9413/10 55 F L IIIB TM IDC - NOS 9.5 3 P A A P P POST,MED 0 P 0.124
125 9438/10 50 F L I MRM IDC - NOS 2 1 A A A P A FREE 0 P 0.014
126 9459/10 50 F R IIB MRM IDC - NOS 9 2 A A A P A FREE 0
127 229/11 44 F L IIA MRM IDC - NOS 3.5 1 A A A P A FREE 0
128 281/11 38 F L IIIC MRM IDC - NOS 5 2 P P P P A FREE 4
129 303/11 40 F L IIA MRM IDC - NOS 4.5 2 A A A P A FREE 0 P 0.52 N
130 340/11 32 F L IIIA MRM IDC - NOS 1.5 2 A P P P A POST 10 P 1.113 N
131 430/11 51 F L IIB MRM IDC - NOS 6 2 A A A A A POST 0
132 511/11 47 F R IIA MRM IDC - NOS 2.5 1 A A P P A FREE 0
133 512/11 51 F L IIIA MRM IDC - NOS 3 2 A P P P A FREE 17
134 549/11 37 F L IIB MRM MAL PHYLLODES 8.5 A A A A P FREE 0
135 701/11 42 F L IIIA MRM IDC - NOS 7 2 A P P A A POST 6
136 738/11 55 F L IIIA SM IDC - NOS 3 2 A P P P A FREE 8
137 784/11 38 F R IIA MRM IDC - NOS 2.5 2 A A A P A POST 0
138 1117/11 62 F L IIA MRM IDC - NOS 2.5 1 A A A P P FREE 0
139 1170/11 52 F L IIA MRM IDC - NOS 5 1 A A A P P POST 0 P 1.22 P
140 1257/11 70 F R IIA MRM IDC - NOS 2 2 A P P P A FREE 1
141 1274/11 38 F L IIIC TM IDC - NOS 6 2 A P P P A POST 6
142 1327/11 59 F R IIA MRM IDC - NOS 2 1 A P P P A FREE 2
143 1358/11 55 F L IIIC MRM IDC - NOS 8 2 A P P P A FREE 4 P 8.131 P
144 1395/11 40 F R IIB MRM IDC - NOS 3 2 A P P P A FREE 1 P 5.549 P
145 1444/11 48 F L IIIA MRM IDC - NOS 2.5 2 A P P P A FREE 13
146 1460/11 75 F L IIIA MRM IDC - NOS 4.5 3 A P P P A FREE 13 P 0.031 P
147 1525/11 61 F R IIIB TM IDC - NOS 6 2 P P P P P POST 0
148    1542/11 52 F R IIIC MRM IDC - NOS 2.5 3 A P P P A FREE 4 P 0.014 P
149 1627/11 27 F L IIIB MRM IDC - NOS 1 1 P A A P P FREE 0
150 1947/11 35 F L IIIB NAC + TM IDC - NOS 10 2 P P P P A ALL 0
151 1997/11 45 F R I SM IDC - NOS 2 2 A P P P A LAT 0
152 2117/11 30 F L IIIA MRM IDC - NOS 2 2 A P P P A FREE 12
153 2174/11 50 F R IIB MRM METAPLASTIC CA 4 A P A A P FREE 1
154 2237/11 60 F R IIA MRM IDC - NOS 4 2 A A A P A FREE 0
155 2376/11 45 F R IIA MRM IDC - NOS 2.5 1 A A A P A FREE 0
156 2516/11 40 F L IIA NAC + MRM IDC - NOS 2 2 A P A P A FREE 2
157 2638/11 57 F R IIA MRM PAPILLARY CA 5 A A A P A FREE 0
158 2676/11 50 F L IIB MRM IDC - NOS 2.5 2 A P A P A LAT 1 N 2.907
159 2787/11 44 F R I MRM IDC - NOS 2 1 A A A P A POST 0 P 2.563
160 2869/11 35 F R IIIA MRM IDC - NOS 5 1 A P P P P FREE 3 P 8.032 N
161 3022/11 85 F R IIB MRM MUCINOUS CA 8 A A A A A FREE 0
162 3193/11 40 F R I MRM IDC - NOS 2 1 A A A A A FREE 0 P 2.34
163 3241/11 48 F R IIIA MRM IDC - NOS 3 2 A P P P A FREE 3 P 1.019 N
164 3408/11 60 F R IIIB TM IDC - NOS 7 3 P P P P A POST 0 P 0.057 N
165 3422/11 42 F R IIA NAC+TM IDC - NOS 2 2 A P P P A POST 0 P 12.19 N
166 3488/11 60 F L IIIC MRM IDC - NOS 2.5 1 A P P A A POST 5 P 1.11 P
167 3693/11 45 F L IIIA MRM IDC - NOS 1 2 A P A A A FREE 3 P 6.7 P
168 3800/11 39 F R I MRM IDC - NOS 1.5 1 A A A P A FREE 0
169 3929/11 55 F R IIB MRM IDC - NOS 3 1 A P P P A FREE 2
170 4157/11 70 F R IIA MRM IDC - NOS 4 1 A A A P A POST 0 N 3.412
171 4216/11 57 F R IIIC MRM IDC - NOS 3 1 A P P P A FREE 5 P 24.01
172 4349/11 70 F R IIIB TM IDC - NOS 3.5 2 P P P P A LAT,POST 0 P 1.002 N
173 4362/11 48 F R IIA MRM IDC - NOS 3 2 A A A P A FREE 0 P 0.613 N
174 4371/11 33 F R IIIB TM IDC - NOS 5 2 P P P P A POST 0 P 0.342 P
175 4371/11 33 F L IIIB MRM IDC - NOS 11 2 P P P P A FREE 14 P 4.972 P
176 4378/11 37 F L IIIA NAC+MRM IDC - NOS 10 3 A P P P P FREE 2 P 0.069 P
177 4430/11 38 F L IIIC NAC+MRM IDC - NOS 4 3 A P P P A FREE 5 N 0.078 P
178 4511/11 65 F R IIIC MRM IDC - NOS 3 2 A P P P A FREE 4 N 2.683 N
179 4552/11 60 F L IIA NAC+MRM IDC - NOS 2 2 A P A A A FREE 1
180 4555/11 40 F R IIIB TM IDC - NOS 6.5 2 A P P A P SUP,MED,LAT,POST 0 P 6.744 P
181 4750/11 33 F L IIA NAC+TM IDC - NOS 2 2 A P A P A FREE 2 N 9.008 N
182 4765/11 45 F R IIA MRM IDC - NOS 4 2 A A A P A FREE 0 P 2.852 P
183 4807/11 68 F L IIB MRM IDC - NOS 4 2 A P A P A FREE 2
184 4930/11 47 F L IIIC MRM IDC - NOS 4 2 A P A P A FREE 4 P 11.58 P
185 4988/11 60 F R IIIB TM IDC - NOS 7 3 P A A P A FREE 0 P 0.011 P
186 4998/11 45 F R IIA MRM IDC - NOS 4 2 A A A P A FREE 0 P 3.97
187 5107/11 70 M L IIIA MRM IDC - NOS 7 3 A P P P A POST,SUP,INF 6
188 5147/11 75 F R IIIC MRM IDC - NOS 2 1 A P P P A FREE 5
189 5170/11 60 F L IIA MRM IDC - NOS 2 2 A P P P A FREE 1
190 5176/11 38 F R IV NAC+MRM IDC - NOS 17 2 P P P P A POST 6
191 5324/11 60 F L IIA MRM IDC - NOS 2.5 2 A A A P A FREE 0
192 5450/11 60 F L IIA MRM IDC - NOS 3 2 A A A P A FREE 0 P 10.49
193 5451/11 54 F R IIIC MRM METAPLASTIC CA 7 A P P P A POST 6
194 5536/11 49 F R IIB MRM IDC - NOS 2.5 2 A P P P A FREE 2
195 5598/11 58 F L IIIA MRM IDC - NOS 5 3 A P P P A FREE 8 P 0.002
196 5791/11 65 F L IIIA MRM IDC - NOS 3 1 A P A A A FREE 10
197 5814/11 50 F L I MRM IDC - NOS 1.5 1 A A A P A FREE 0
198 5858/11 50 F L IIIC MRM IDC - NOS 2 2 A P A P A FREE 5
199 5871/11 48 F R IIA NAC+SM IDC - NOS 3 2 A A A A P FREE 0
200 5949/11 55 F R IIIB TM IDC - NOS 12 3 P P A P A FREE 0
201 5988/11 48 F L IIA NAC+MRM IDC - NOS 2.5 2 A P P P A FREE 0
202 5992/11 55 F L I MRM PAPILLARY CA 1.5 A A A A A FREE 0
203 6051/11 51 F R I MRM IDC - NOS 1.5 1 A A A P A FREE 0
204 6157/11 50 F R IIB MRM IDC - NOS 4 2 A P A P A FREE 1
205 6162/11 45 F L IIIB SM IDC - NOS 7.5 2 P A A P A POST 0
206 6308/11 50 F R IIA MRM IDC - NOS 3 2 A P P P A POST 0
207 6524/11 42 F R IIIA NAC+MRM IDC - NOS 3 3 A P P P P FREE 3 P 0.013
208 6595/11 76 F L IIIA MRM IDC - NOS 5 1 A P P P P FREE 3
209 6609/11 47 F R IIA MRM IDC - NOS 4.5 2 A A A P A FREE 0
210 6646/11 54 F R IIIA MRM IDC - NOS 3 3 A P P A A FREE 3
211 6685/11 40 F R IIB MRM IDC - NOS 6 1 A A A A A FREE 0
212 6707/11 45 F R IIB NAC+MRM IDC - NOS 3 2 A P P P P FREE 2
213 6722/11 25 F R IIA NAC+MRM IDC - NOS 2 2 A A A P A FREE 0
214 6854/11 50 F L IIIB NAC+MRM IDC - NOS 15 3 P P P A A POST 10 N 0.062
215 6885/11 35 F R IIA MRM IDC - NOS 3 2 A P A P A FREE 0
216 6908/11 60 F R IIIA MRM IDC - NOS 3 1 A P P P P FREE 3
217 6973/11 43 F R I MRM APOCRINE CA 1.5 A A A A P FREE 0
218 7040/11 55 F L IIB MRM IDC - NOS 10 1 A P P P A FREE 0
219 7075/11 30 F L IIA RT+NAC+MRM IDC - NOS 1.5 3 A P P P A FREE 2 P 0.025
220 7231/11 45 F L IIIC NAC+MRM IDC - NOS 5 2 A P P P A POST 7
221 7274/11 50 F R IIA NAC+MRM IDC - NOS 1.5 2 A P A P P FREE 2
222 7278/11 45 F R IIIB MRM IDC - NOS 3.5 2 P P P P A FREE 13
223 7301/11 35 F L IIA NAC+MRM IDC - NOS 4 2 A A A P A FREE 0
224 7466/11 40 F R IIIC MRM IDC - NOS 3 2 A P P P A FREE 5
225 7495/11 65 F L IIIB MRM IDC - NOS 9 1 P A A A P FREE 0 N 0.043
226 7692/11 58 F L IIIB MRM METAPLASTIC CA 10 P P P P P FREE 0
227 7709/11 45 F L IIB MRM MEDULLARY CA 2.5 A P A A A FREE 1
228 7764/11 70 F R IIB MRM MUCINOUS CA 3.5 A P A A A FREE 1
229 7935/11 57 F L IIIB MRM IDC - NOS 4 2 P A A A P FREE 0
230 7947/11 60 F L IIA MRM IDC - NOS 3 1 A P P P P FREE 0 N 3.2
231 7973/11 40 F L I MRM IDC - NOS 2 2 P A P A A FREE 0 N 14.62
232 7977/11 63 F L IIIB MRM IDC - NOS 10 1 P P A P P SUP,POST 3 P 1.003
233 7989/11 55 F R IIIB PSM IDC - NOS 4 2 P A A P P POST 0 N 16.36
234 8044/11 55 F R IIIB NAC+MRM IDC - NOS 2.5 2 P P A P A FREE 3
235 8104/11 72 F R I MRM IDC - NOS 1.5 1 A P P A A FREE 0 N 2.316
236 8112/11 58 F L IIA NAC+MRM IDC - NOS 3 2 A A P A A FREE 0
237 8313/11 45 F R IIIB NAC+MRM IDC - NOS 3 2 P P P A A POST 0
238 8433/11 47 F R IIA MRM IDC - NOS 4 1 A P P A A FREE 0
239 8489/11 46 F R IIIB NAC+MRM IDC - NOS 1 2 P P A A A FREE 1
240 8544/11 56 F L IIB NAC+MRM IDC - NOS 5 1 A P P A A FREE 2
241 8672/11 42 F L IIA MRM IDC - NOS 3.5 1 A A A P P FREE 0
242 8740/11 37 F L IIB MRM IDC - NOS 4 1 A P A P A FREE 1
243 8758/11 50 F R IIIB MRM IDC - NOS 9 3 P P A P A POST 1 P 0.031
244 8794/11 58 F R IIIA MRM IDC - NOS 3 2 A P P P A FREE 11
245 8835/11 48 F L IIIB MRM IDC - NOS 2 1 P A A A A FREE 0
246 8848/11 45 F R IIA MRM IDC - NOS 3 2 A A A P A FREE 0
247 8849/11 50 F R IIIB NAC+MRM IDC - NOS 1 2 P P A A A FREE 0
248 8923/11 53 F L IIB MRM IDC - NOS 3 2 A P A P A FREE 1
249 9128/11 38 F L IIIC NAC+MRM IDC - NOS 5 3 A P P P P FREE 5 P 0.24
250 9218/11 58 F L IIIA MRM IDC - NOS 8 1 A P A A A POST 2 N 1.1
251 9311/11 50 F R IIIC MRM IDC - NOS 3 1 A P P P A FREE 5
252 9344/11 55 F L IIIB TM IDC - NOS 9 2 P P A A A FREE 1
253 9406/11 60 F L IIIB NAC+MRM IDC - NOS 2.5 1 P P P P A FREE 2
254 9492/11 35 F R IIA MRM IDC - NOS 4 1 A P A P A FREE 0
255 9552/11 46 F L IIIC MRM IDC - NOS 6 2 P P P P A FREE 8
256 9598/11 46 F R IIIB NAC+MRM IDC - NOS 6 2 P P P P A POST 0
257 9734/11 68 F L IIA MRM IDC - NOS 3 1 A A A A A FREE 0
258 9744/11 48 F L IIIA MRM IDC - NOS 2 2 A P P A P FREE 3
259 9852/11 60 F R IV TM IDC - NOS 12 2 P P P P A POST 9
260 172/12 48 F R IIIC MRM IDC - NOS 2.5 2 A P P A A FREE 5
261 306/12 40 F R IIIA MRM IDC - NOS 2.5 2 A P P A A POST 3
262 384/12 51 F L IIA NAC+MRM IDC - NOS 1 3 A P A A A FREE 1
263 474/12 48 F L IIIB MRM IDC - NOS 5 2 P P P A P FREE 2
264 689/12 45 F R I MRM IDC - NOS 1.5 1 A A A P A FREE 0
265 733/12 71 F R IIB MRM IDC - NOS 3.5 2 A P A A A FREE 1
266 792/12 56 F L IIA NAC+MRM IDC - NOS 2.5 3 A P P A P FREE 0 N 0.017
267 853/12 65 F R IIA NAC+MRM IDC - NOS 2.5 1 A A A A P FREE 0
268 948/12 45 F R IIA MRM IDC - NOS 4 3 A A A P P FREE 0 P 0.114
269 1156/12 48 F R IIA MRM IDC - NOS 2.5 2 A P P A P FREE 0
270 1164/12 39 F R IIA MRM NEUROENDOCRINE CA 4 A A A A P FREE 0
271 1249/12 48 F R IIIA MRM IDC - NOS 2 2 A P P A A FREE 3
272 1353/12 44 F R IIIB MRM APOCRINE CA 8 P A A A A FREE 0
273 1562/12 54 F L IIB MRM IDC - NOS 3 2 A P A A A FREE 1
274 1655/12 40 F L IIIA MRM IDC - NOS 3.5 2 A P P A A FREE 3
 ABSTRACT 
 
 
AIM: 
 
The aim of the present study was to identify the incidence and distribution of 
breast carcinoma in patients admitted in the Government General Hospital, 
Chennai fromJanuary 2010 to February 2012 and to evaluate the expression of p53 
by IHC and to study the E Cadherin and HoxD10 gene expression by PCR in 
invasive ductal carcinoma NOS and correlate the findings withhistological grade 
and other clinicopathologicalparameters. 
MATERIALS AND METHODS:  
20 cases of each grade from Invasive ductal carcinoma NOS subtype who 
had undergone mastectomy were randomly selected from thetotal cases and their 
representative formalin fixed paraffin embedded tissue samples were subjected to 
p53 immunohistochemical analysis and to HoxD10 & E Cadherin gene analysis by 
PCR.The results were correlated with histological grade and other 
clinicopathological features. 
RESULTS:  
P53 over expression and HoxD10 gene down regulation showed statistically 
significant association with high grade tumours. Though not statistically 
significant, CDH1 gene mutation was more frequent among tumours with 
increasinggrade. The mean relative concentration of HoxD10 mRNA was lower in 
the p53 and CDH1 mutation positive group.CDH1 gene mutation was found to be 
more common among thep53 positive cases than the p53 negative cases. 
CONLUSION: 
 Molecular analysis of breast carcinoma may serve as an important 
prognostic tool to predict patient outcome and for the development of targeted 
therapy in this new era of early cancer detection. 
KEYWORDS:Breast carcinoma, p53, HoxD10, E Cadherin. 
 
 
 
